



Europass Curriculum Vitae

Personal information

Surname(s) / First name(s) **Gronchi Alessandro**
Address(es) Istituto Nazionale Tumori, via G. Venezian 1, 20133, Milano, Italy
Telephone(s) +39 02 2390 3234
Fax(es) +39 02 2390 2404
E-mail alessandro.gronchi@istitutotumori.mi.it
Nationality Italian
Date of birth 11 June 1968
Gender Male

Work experience

Dates From July 2011
Occupation or position held **Chair of the Sarcoma Service**
Main activities and responsibilities Coordinating the surgical activity of sarcoma & peritoneal surface malignancies patients, treated within a surgical oncology unit devoted to sarcoma and peritoneal surface malignancies
Name and address of employer **Istituto Nazionale Tumori**, via G. Venezian 1, 20133 **Milano**, Italy
Type of business or sector Surgical oncology
Dates From April 2001 to June 2011
Occupation or position held **In charge of the sarcoma service**
Main activities and responsibilities Coordinating the surgical activity of sarcoma patients, treated within a surgical oncology unit devoted to melanoma and sarcoma
Name and address of employer **Istituto Nazionale Tumori**, via G. Venezian 1, 20133 **Milano**, Italy
Type of business or sector Surgical oncology
Dates From November 1999
Occupation or position held **Attending surgeon**
Main activities and responsibilities Full staff position as surgical oncologist
Name and address of employer **Istituto Nazionale Tumori**, via G. Venezian 1, 20133 **Milano**, Italy
Type of business or sector Health care: surgical oncology
Dates From July 1996 to October 1999
Occupation or position held **Clinical fellow / Associate Physician**
Main activities and responsibilities Non full staff positions as Surgical oncologist
Name and address of employer Istituto Nazionale Tumori, via G. Venezian 1, 20133 Milano, Italy
Type of business or sector Health care: surgical oncology
Dates From July 1994 to June 1996
Occupation or position held **Attending surgeon**
Main activities and responsibilities General surgery and Gynecology

Name and address of employer **St. Mary's Hospital Lacor – Gulu - Uganda**
Type of business or sector General Surgery and Gynecology

Education and training

Dates	From 1992 to 1997
Title of qualification awarded	Board certificate in General Surgery
Principal subjects/occupational skills covered	General Surgery
Name and type of organisation providing education and training	University, Milan, Italy
Level in national or international classification	ISCED 5A (Field of Education: 72)
Dates	1993
Title of qualification awarded	Italian Medical Licence
Principal subjects/occupational skills covered	Medicine
Name and type of organisation providing education and training	University, Milano, Italy
Dates	From 1986 to 1992
Title of qualification awarded	Medical Degree (cum laude)
Principal subjects/occupational skills covered	Medicine
Name and type of organisation providing education and training	University, Milano, Italy
Level in national or international classification	ISCED 5A (Field of Education: 72)

Personal skills and competences

Mother tongue(s)

Italian

Other language(s)

Self-assessment

European level (*)

English

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production			
C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user	C1	Proficient user

(*) Common European Framework of Reference for Languages

Additional information

- National Scientific Abilitation for full professor of General Surgery (settore concorsuale 06/C1) until March 30th 2024
- Adjunct Professor of the General Surgery Residency Program, Milan University, hepatobiliopancreatic surgery and complex surgical oncology programs
- Member of the Sarcoma Task Force of the European Society for Medical Oncology (ESMO)
- Member of the Board of Directors of the Connective Tissue Oncology Society (CTOS) 2009-2012, treasurer for 2013, secretary for 2014, vice president for 2015, president for 2016, past president 2017
- Member of the Board of Directors of the Italian Sarcoma Group (ISG)
- Member of the Board of Directors of the Italian Society of Surgical Oncology (SICO), president elect 2019-2021
- Chair of the EORTC Soft Tissue and Bone Sarcoma Group 2015-2017; Past Chair 2018-2019
- Member of the International Committee, Society of Surgical Oncology (SSO) 2009-2011
- Member of Sarcoma Disease Site Working Group, Society of Surgical Oncology (SSO) 2018-2021
- Section editor of Bone & Soft Tissue Sarcoma for the Annals of Surgical Oncology 2009-2014
- Associate editor of the Sarcoma Journal
- Associate editor of Clinical Sarcoma Research
- Associate editor of Journal of Surgical Oncology
- Honorary Member of the Polish Society of Surgical Oncology (PSSO)
- Member of the following professional/scientific societies:
 - European Society for Medical Oncology (ESMO)
 - European Muscolo-Skeletal Oncology Society (EMSOS)
 - Society of Surgical Oncology (SSO)
 - American Society of Clinical Oncology (ASCO)
 - European Surgical Association (ESA)
 - Connective Tissue Oncology Society (CTOS)
 - European Society of Surgical Oncology (ESSO)
 - Italian Society of Surgical Oncology (SICO)
 - Italian Society of Surgery (SIC)

Publications: see Annexes 1-2-3-4

Experience in clinical trials: see Annex 5

Annexes

Annex 1: List of **Medline-indexed scientific publications, in English**

Annex 2: List of **Medline-non indexed scientific publications, in English**

Annex 3: List of **Book chapters, in English**

Annex 4: List of **Books, in Italian**

Annex 5: List of **Clinical Trials Performed**

Annex 1

List of Medline-indexed scientific publications, in English

1. Bozzetti F., Bertario L., Rossetti C., Gennari L., Andreola S., Baratti D., **Gronchi A.** Surgical treatment of locally recurrent rectal carcinoma. *Disease of the Colon Rectum* 1997; 40 (12): 1421-1424.
2. Bozzetti F., Baratti D., Andreola S., Zucali R., Schiavo M., Spinelli P., **Gronchi A.**, Valvo F., Mariani L., Gennari L. Preoperative Radiation Therapy for T2-T3 cancers of the middle-to-lower rectum. *Cancer* 1999; 86 (3): 398-404.
3. Azzarelli A., **Gronchi A.**, Bertulli R., Tesoro Tess J.D., Baratti D., Pennacchioli E., Dileo P., Rasponi A., Pilotti S., Casali P.G. Low-dose chemotherapy with Methotrexate and Vinblastine for advanced aggressive fibromatosis. *Cancer* 2001, 92 (5): 1259-1264.
4. Mezzelani A., Mariani L., Tamborini E., Agus V., Riva C., Lo Vullo S., Fabbri A., Stumbo M., Azzarelli A., Casali P.G., **Gronchi A.**, Sozzi G., Pierotti M.A., Pilotti S. SYT-SSX fusion genes and prognosis in synovial sarcoma. *Br J of Cancer* 2001, 85 (10): 1535-9.
5. Ferrari A., Casanova M., Bisogno G., Mattke A., Meazza C., **Gronchi A.**, Cecchetto G., Fidani P., Kunz D., Treuner J., Carli M. Hemangiopericytoma in pediatric age: a report from the italian and german soft tissue sarcoma cooperative group. *Cancer* 2001, 92 (10): 2692-2698.
6. Tamborini E., Agus V., Perrone F., Papini D., Romanò R., Pasini B., **Gronchi A.**, Colecchia M., Rosai J., Pierotti M.A., Pilotti S. Lack of SYT-SSX fusion transcripts in malignant peripheral nerve sheath tumors on RT-PCR analysis of 38 archival cases. *Lab Invest.* 2002, 82 (5): 609-618.
7. Deraco M, **Gronchi A.**, Mazzaferro V, Inglese MG, Pennacchioli E, Kusamura S, Rizzi M, Anselmi RA Jr, Vaglini M. Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei. *Tumori.* 2002, 88(5):370-5.
8. **Gronchi A.**, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, Bertulli R, Fiore M, Olmi P, Santinami M, Rosai J. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. *J Clin Oncol.* 2003; 21(7):1390-7.
9. Baratti D, **Gronchi A.**, Pennacchioli E, Lozza L, Colecchia M, Fiore M, Santinami M. Chordoma: natural history and results in 28 patients treated at a single institution. *Ann Surg Oncol.* 2003; 10(3):291-6.
10. Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, Navarra P, Collini P, **Gronchi A.**, Olmi P, Fossati-Bellani F, Casali PG. Rhabdomyosarcoma in adults: a retrospective analysis of 171 patients treated at a single institution. *Cancer* 2003; 98 (3): 571-580.
11. Collini P, Mezzelani A, Modena P, Dagrada P, Tamborini E, Luksch R, **Gronchi A.**, Navarra P, Sozzi G, Pilotti S. Evidence of neural differentiation in a case of post-therapy primitive neuroectodermal tumor/Ewing sarcoma of bone. *Am J Surg Pathol* 2003 Aug;27(8):1161-1166.
12. Deraco M, Kusamura S, **Gronchi A.** [Cytoreductive surgery (peritonectomy) and intraperitoneal hyperthermic chemotherapy: an innovative and effective approach to the treatment of pseudomyxoma peritonei]. *Tumori.* 2003 89(4 Suppl): 54-5.
13. Perrone F, Tabano S, Colombo F, Dagrada G, Biringelli S, **Gronchi A.**, Colecchia M, Pierotti MA and Pilotti S. p15INK4b, p14ARF and p16INK4a inactivation in sporadic and NF1-related Malignant Peripheral Nerve Sheath Tumors. *Clin Cancer Res.* 2003 Sept.; 9(11): 4132-4138.
14. Tamborini E, Bonadiman L, Greco A, **Gronchi A.**, Riva C, Bertulli R, Casali PG, Pierotti MA and Pilotti S. Alternative expression of ligand-activated kit and PDGFRbeta tyrosine kinase receptors in synovial sarcoma. *Clin Cancer Res* 2004 Feb; 10(3): 938-943.
15. **Gronchi A.**, Diment J, Colecchia M, Fiore M and Santinami M. Atypical pleomorphic epithelioid angiomyolipoma localized to the pelvis: a case report and review of the literature. *Histopathology* 2004 Mar; 44(3): 292-295.
16. Rossi CR, Deraco M, De Simone M, Mocellin S, Pilati P, Foletto M, Cavaliere F, Kusamura S, **Gronchi A.**, Lise M. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis. *Cancer* 2004 May 1;100(9):1943-50.
17. **Gronchi A.**, Casali PG, Fiore M, Mariani L, Lo Vullo S, Bertulli R, Colecchia M, Lozza L, Olmi P, Santinami M and Rosai J. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. *Cancer* 2004, 100(11): 2448-2455.
18. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, **Gronchi A.**, Bertulli R, Colecchia M, Casali PG, Pierotti M and Pilotti S. A new mutation in the ATP pocket of Kit receptor is responsible for acquired resistance to Imatinib in a patient with gastrointestinal stromal tumor (GIST). *Gastroenterology* 2004, 127(1):294-9.
19. Ferrari A, **Gronchi A.**, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, Casali PG. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. *Cancer* 2004, 101(3): 627-634.
20. Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, **Gronchi A.**, Orlandi R, Ripamonti C, Spreafico C, Alberti D, Bertieri R, Bertulli R, Coco P, Colecchia M, Fumagalli E, Greco A, Grosso F, Negri T, Olmi P, Pierotti MA, Pilotti S. Imatinib mesylate in chordoma. *Cancer* 2004, 101(9):2086-97.
21. Kusamura S, Raspagliesi F, Baratti D, **Gronchi A.**, Casali P, Deraco M. Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: a feasibility study. *J Chemother.* 2004, 16 Suppl 5:19-22.

22. Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, Casali PG and **Gronchi A**. Validation and adaptation of a nomogram for predicting survival of extremity soft tissue sarcoma using a three grade system. *Cancer* 2005, 103(2):402-408.
23. **Gronchi A**, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, Bertulli R, Collini P, Lozza L, Olmi P and Rosai J. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: A series of 911 consecutive patients treated at a single institution. *J Clin Oncol* 2005, 23(1):96-104.
24. Diment J, Tamborini E, Casali PG, **Gronchi A**, Carney JA and Colecchia M. Carney Triad: case report and molecular analysis of gastric tumor. *Human Path* 2005, 36: 112-116.
25. Ferrari A, Casanova M, Collini P, Meazza C, Lukcsh R, Massimino M, Cefalo G, Terenziani M, Spreafico F, Catania S, Gandola L, **Gronchi A**, Mariani L and Fossati-Bellani F. Adult-type soft tissue sarcoma in pediatric age: experience at the Istituto Nazionale Tumori in Milan. *J Clin Oncol.* 2005, 23(18): 4021-4030.
26. Blay JY, Bonvalot S, Casali PG, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, **Gronchi A**, Hogendoorn PCW, Joensuu H, Le Cesne A, Joan Mac Clure, Joan Maurel, Nina Nupponen, Isabelle Ray-Coquard, Peter Reichardt, Raf Sciot, Sigrid Stroobants, Martine van Glabbeke, Allan van Oosterom, Georges D Dimetri. A consensus meeting for the management of gastro-intestinal stromal tumors. Report from the ESMO GIST consensus conference of March 20-21st, 2004. *Ann Oncol.* 2005 Apr;16(4):566-78.
27. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V, Lagonigro MS, Gabanti E, Caramuta S, Greco A, Torre GD, **Gronchi A**, Pierotti MA, Pilotti S. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. *Cancer.* 2005, 104: 159-169.
28. Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, Collini P, Olmi P, Casali PG and **Gronchi A**. Dermatofibrosarcoma Protuberans treated at a single institution: a surgical disease with a high cure rate. *J Clin Oncol.* 2005; 23:7669-75.
29. Casanova M, Ferrari A, Collini P, Bisogno G, Aleggio R, Cecchetto G, **Gronchi A**, Meazza C, Garaventa A, Di Cataldo A, Carli M. Epithelioid Sarcoma in children and adolescents: a report from the Italian soft tissue sarcoma committee. *Cancer.* 2006; 106(3):708-17.
30. Fiore M, Casali PG, Miceli R, Mariani L, Bertulli R, Lozza L, Collini P, Olmi P, Mussi C and **Gronchi A**. Prognostic effect of re-excision in adult soft tissue sarcoma of the extremities. *Ann Surg Oncol.* 2006; 13(1):110-7.
31. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S and **Gronchi A**. Malignant peripheral nerve sheath tumours: prognostic factors and survival in a series of patients treated at a single institution. *Cancer.* 2006; 107(5):1065-1074.
32. Tamborini E, Pricl S, Negri T, Lagonigro MS, Miselli F, Greco A, **Gronchi A**, Casali PG, Ferrone M, Fermeglia M, Carbone A, Pierotti MA, Pilotti S. Functional analyses and molecular modeling of two c-Kit mutations responsible for Imatinib secondary resistance in GIST patients. *Oncogene.* 2006; 25(45): 6140-6146.
33. Costa A, Daidone MG, Daprao L, Villa R, Cantù S, Pilotti S, Mariani L, **Gronchi A**, Henson JD, Reddel RR and Zaffaroni N. Telomere maintenance mechanisms in liposarcoma: association with histologic subtypes and disease progression. *Cancer Res.* 2006; 66(17):8918-24.
34. Tamborini E, Miselli F, Negri T, Lagonigro S, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, **Gronchi A**, Perrone F, Carbone A, Pierotti MA, Casali PG and Pilotti S. Molecular and biochemical analyses of PDGFRB, PDGFRA and KIT receptors in chordoma. *Clin Cancer Res.* 2006; 12(23):6920-8.
35. Pennacchioli E, Deraco M, Mariani L, Fiore M, Mussi C, Collini P, Olmi P, Casali PG, Santinami M and **Gronchi A**. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. *Ann Surg Oncol* 2007; 14(2): 553-9.
36. **Gronchi A**, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S and Casali PG. Surgery of residual disease following molecular targeted therapy with Imatinib mesylate in advanced/metastatic GIST. *Ann Surg* 2007; 245: 341-346.
37. Miselli F, Casieri P, Negri T, Orsenigo M, Lagonigro MS, **Gronchi A**, Fiore M, Casali PG, Bertulli R, Carbone A, Pienotti MA, Tamborini E and Pilotti S. c-Kit/PDGFRα gene status alterations possibly related to primary Imatinib resistance in Gastrointestinal Stromal Tumors. *Clin Cancer Res* 2007; 13(8):2369-77.
38. Tamborini E, Casieri P, Miselli F, Orsenigo M, Negri T, Piacenza C, Stacchiotti S, **Gronchi A**, Pastorino U, Pierotti MA and Pilotti S. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. *J Pathol* 2007; 212(2):227-235.
39. **Gronchi A**, Miceli R, Fiore M, Collini P, Lozza L, Grosso F, Mariani L and Casali PG. Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. *Ann Surg Oncol* 2007; 14(5):1583-90.
40. Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, Collini P, Lozza L, Mariani L, Casali PG and **Gronchi A**. Myxoid/round cell and pleomorphic liposarcoma: prognostic factors and survival in a series of patients treated at a single institution. *Cancer* 2007; 109: 2522-2531.
41. Casali PG, Stacchiotti S, Sangalli C, Olmi P, **Gronchi A**. Chordoma. *Curr Opin Oncol* 2007; 19(4): 367-370.
42. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero TC, Jimeno J, D'Incalci M, **Gronchi A**, Fletcher JA, Pilotti S, Casali PG. Efficacy of trabectedin (ET-743) in advanced pre-treated myxoid liposarcomas. *Lancet Oncol* 2007; 8(7): 595-602.

43. Casanova M, Meazza C, **Gronchi A**, Fiore M, Zaffignani E, Podda M, Collini P, Gandola L, Ferrari A. Soft tissue sarcoma of the extremities in patients of pediatric age. *J Child Orthop* 2007; 1(3):195-203.
44. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, **Gronchi A**, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J; NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. *J Natl Compr Canc Netw*. 2007; 5 Suppl 2:S1-29.
45. **Gronchi A**, Olmi P and Casali PG. Combined modalities approach for localized adult extremity soft tissue sarcoma. *Expert Rev. Anticancer Ther* 2007; 7(8): 1135-1144.
46. Signoroni S, Frattini M, Negri T, Pastore E, Tamborini E, Casieri P, Orsenigo M, Da Riva L, Radice P, Sala P, **Gronchi A**, Bertario L, Pierotti MA and Pilotti S. Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as potential targets in treating Aggressive Fibromatosis. *Clin Cancer Res* 2007; 13(17): 5034-5040.
47. Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, Olmi P, Collini P, Redaelli S, Fiore M and **Gronchi A**. Epithelioid Sarcoma: Prognostic Factors and Survival in a series of Patients Treated at a Single Institution. *Ann Surg Oncol* 2007; 14(12):3542-51.
48. Ferrari A, Miceli R, Casanova M, **Gronchi A**, Collini P, Meazza C, Zaffignani E, Massimo M, Spreafico F, Mariani L. Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma. *Eur J Cancer*. 2007; 43(18): 2691-2697.
49. Venturini L, Erdas R, Costa A, **Gronchi A**, Pilotti S, Zaffaroni N and Daidone MG APB detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcoma. *J Pathol* 2008; 214(4): 410-414.
50. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2008 May;19 Suppl 2:ii35-8.
51. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY; ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2008 May;19 Suppl 2:ii89-93.
52. Fiore M, Locati P, Mussi C, Guarino A, Piva L, Santinami M and **Gronchi A**. Banked venous homograft replacement of the inferior vena cava for primary leiomyosarcoma. *Eur J Surg Oncol* 2008; 34(6): 720-724.
53. Mussi C, Schildhaus HU, **Gronchi A**, Wardelmann E and Hohenberger P. Therapeutic Consequences From Molecular Biology For GIST Patients Affected By Neurofibromatosis Type 1. *Clin Cancer Res* 2008; 14(14): 4550-4555.
54. Mussi C, Collini P, Miceli R, Barisella M, Mariani L, Fiore M, Casali PG and **Gronchi A**. Prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of patients surgically treated at a single institution. *Cancer* 2008; 113: 1657-1665.
55. Miselli F, Negri T, **Gronchi A**, Losa M, Conca E, Brich S, Fumagalli E, Fiore M, Casali PG, Pierotti MA, Tamborini E, Pilotti S. Is autophagy rather than apoptosis the regression driver in Imatinib-treated gastrointestinal stromal tumours ? *Transl Oncol* 2008; 1(4): 177-186.
56. Negri T, Bozzi F, Conca E, Brich S, **Gronchi A**, Bertulli R, Fumagalli E, Pierotti MA, Tamborini E, Pilotti S. Oncogenic and ligand-dependent activation of KIT/PDGFRα in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). *J Pathol* 2009; 217:103-112.
57. **Gronchi A**, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E, Mariani L and Casali PG. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. *J Clin Oncol* 2009; 27(1): 24-30.
58. Ferrari A, Miceli R, Casanova M, Meazza C, Zaffignani E, **Gronchi A**, Piva L, Collini P, Podda M, Massimo M, Luksch R, Cefalo G, Terenziani M, Spreafico F, Polastri D, Mariani L. Soft Tissue Sarcoma of childhood and adolescence: the prognostic role of tumor size changes in relation to the patient's body size. *J Clin Oncol* 2009; 27(3): 371-376..
59. Stacchiotti S, Tamborini E, Marrari A, Brich S, Arisi Rota S, Orsenigo M, Crippa F, Morosi C, **Gronchi A**, Pierotti MA, Casali PG and Pilotti S. Response to sunitinib malate in advanced alveolar soft part sarcoma (ASPS). *Clin Cancer Res* 2009, 15(3): 1096-1104
60. Pennacchioli E, Fiore M and **Gronchi A**. Hyperthermia as a adjunctive treatment for soft tissue sarcoma. *Expert Rev. Anticancer Ther* 2009, 9(2): 199-210
61. Forni C, Minuzzo M, Viridis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, **Gronchi A**, Aman P, Casali PG, D'Incalci M, Pilotti S and Mantovani R. Trabectedin (ET-743) promotes differentiation of myxoid liposarcoma tumors. *Mol Cancer Ther* 2009, 8(2): 449-457
62. **Gronchi A**, Bonvalot S, Le Cesne A and Casali PG. Resection of uninvolved adjacent organs can be part of surgery for retroperitoneal soft tissue sarcoma. *J Clin Oncol* 2009, 27(12):2106-2107
63. **Gronchi A**, Judson I, Nishida T, Poveda A, Martin J, Reichardt P, Casali PG, Le Cesne A, Hohenberger P, Blay JY. Adjuvant treatment with Imatinib for GIST: solid ground or still quicksand ? A comment on behalf of the EORTC soft tissue and bone sarcoma group, the Italian sarcoma Group, the NCRi Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group, the Spanish Sarcoma Group (GEIS). *Eur J Cancer* 2009, 45(7):1103-1106.
64. Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, Piovesan C, Dileo P, Torri V, **Gronchi A** and Casali PG Tumor response assessment in high grade soft tissue sarcomas (STS): a pilot study to assess the correlation between radiological and pathological response using both RECIST and Choi's criteria. *Radiology* 2009, 251(2): 447-456.

65. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG and **Gronchi A**. Preoperative Imatinib mesylate for unresectable or locally advanced primary Gastrointestinal Stromal Tumors (GIST). *Eur J Surg Oncol* 2009, 35: 739-745.
66. Thomas DM, O'Sullivan B and **Gronchi A**. Current concepts and future perspectives in Retroperitoneal Soft Tissue Sarcoma management. *Expert Rev Anticancer Ther* 2009, 9(8):1145-57
67. Reichardt P, Hogendoorn PC, Tamborini E, Loda M, **Gronchi A**, Poveda A, Schöffski P. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. *Semin Oncol*. 2009, 36(4):290-301.
68. Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Pécoux C, Casali PG, Le Cesne A, **Gronchi A** and Bonvalot S. Desmoid-Type Fibromatosis: a front-line conservative approach to select patients for surgical treatment. *Ann Surg Oncol* 2009, 16(9): 2587-2593.
69. Grosso F, Sanfilippo R, Viridis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D'Incalci M, **Gronchi A**, Pilotti S and Casali PG. Trabectedin in Myxoid Liposarcomas (MLS): a long-term analysis of a single institution series. *Ann Oncol* 2009, 20(8):1439-44
70. Colombo C and **Gronchi A**. Desmoid-type fibromatosis: what works best? *Eur J Cancer* 2009, 45 Suppl 1: 466-467.
71. Conca E, Negri T, **Gronchi A**, Fumagalli E, Tamborini E, Pavan GM, Fermeglia M, Pierotti MA, Pricl S and Pilotti S. Activate and Resist: L576P in GIST. *Mol Cancer Ther* 2009, 8(9):2491-2495
72. Stacchiotti S, Marrari A, Tamborini E, Palassini E, Viridis E, Messina A, Crippa F, Morosi C, **Gronchi A**, Pilotti S and Casali PG. Response to imatinib plus sirolimus in advanced chordoma. *Ann Oncol* 2009; 20(11):1886-1894
73. Perrone F, Da Riva L, Orsenigo M, Losa M, Jocolle G, Millefanti C, Pastore E, **Gronchi A**, Pierotti MA, and Pilotti S. PDGFRA, PDGFRB, EGFR and downstream signalling activation in malignant peripheral nerve sheath tumour. *Neuro Oncology* 2009; 11(6): 725-736
74. Stacchiotti S, Casali PG, Lo Vullo S, Mariani L, Palassini E, Mercuri M, Alberghini M, Pilotti S, Zanella L, **Gronchi A** and Picci P. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centres. *Ann Surg Oncol* 2010; 17: 211-219
75. Meazza C, Bisogno G, **Gronchi A**, Fiore M, Cecchetto G, Alaggio R, Milano GM, Casanova M, Carli M, Ferrari A. Aggressive fibromatosis in children and adolescents: the italian experience. *Cancer* 2010; 116(1):233-240
76. Mussi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali PG, Fiore M, Hohenberger P and **Gronchi A**. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? *Ann Oncol* 2010; 21(2):403-408
77. **Gronchi A**, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, Fiore M and Casali PG. Extremity soft tissue sarcoma in a series of patients treated at a single institution: the local control directly impacts survival. *Ann Surg* 2010; 251: 512-517
78. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, **Gronchi A**, Viridis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M and Allavena P. Anti-tumor and anti-inflammatory effects of Trabectedin on human myxoid liposarcoma cells. *Cancer Res* 2010; 70(6): 2235-2244
79. **Gronchi A**, Blay JY and Trent JC. The Role of High-Dose Imatinib in the Management of Patients with Gastrointestinal Stromal Tumor (GIST). *Cancer* 2010; 116(8):1847-1858
80. Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, **Gronchi A** and Casali PG. Tumor response to Sunitinib Malate observed in Clear Cell Sarcoma. *Ann Oncol* 2010; 21(5):1130-1131
81. Ardoino I, Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, Collini P, Stacchiotti S, Casali PG and **Gronchi A**. Histology-Specific Nomogram for Primary Retroperitoneal Sarcoma. *Cancer* 2010; 116: 2429-2436
82. Stacchiotti S, Negri T, Palassini E, Conca E, **Gronchi A**, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG and Pilotti S. Sunitinib malate and Figitumumab in solitary fibrous tumor (SFT): patterns and molecular bases of tumor response. *Mol Cancer Ther* 2010; 9(5): 1286-1297
83. Bonvalot S, Miceli R, Berselli M, Causeret S, Colombo C, Mariani L, Bouzaïene H, Le Pécoux C, Casali PG, Le Cesne A, Fiore M and **Gronchi A**. Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma carried out at high volume centers is safe and associated to an improved local control. *Ann Surg Oncol* 2010; 17: 1507-1514
84. Venturini L, Motta R, **Gronchi A**, Daidone MG and Zaffaroni N. Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. *BMC Cancer* 2010; 10: 254
85. Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET. Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010; 21 Suppl 5:v198-203
86. Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010; 21 Suppl 5:v98-102.
87. Hogendoorn PC; ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Hogendoorn PC, Jurgens H, Paulussen M, Rozeman L, Taminiau AH, Whelan J, Vanel D. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010; 21 Suppl 5:v204-13.
88. Tamborini E, Viridis E, Negri T, Orsenigo M, Brich S, Conca E, **Gronchi A**, Stacchiotti S, Manenti G, Casali PG, Pierotti MA and Pilotti S. Analysis of Receptor Tyrosine Kinases (RTK) and Downstream Pathways in Chordomas. *Neuro Oncol* 2010; 12(8): 776-789

89. Frapolli R, Tamborini E, Viridis E, Bello E, Tarantino E, Marchini S, Grosso F, Sanfilippo R, **Gronchi A**, Tercero J, Peloso G, Casali PG, Pilotti S, D'Incalci M. Novel models of Myxoid Liposarcoma Xenografts mimicking the biological and pharmacological features of human tumors. *Clin Cancer Res* 2010;16(20):4958-4967
90. Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, Casali PG and **Gronchi A**. Alveolar Soft Part Sarcoma: clinical presentation, treatment and outcome in a series of 33 patients at a single institution. *Ann Surg Oncol* 2010; 17: 3229-3233
91. Gatta G, Capocaccia R, Trama A, Martinez-Garzia C; RARECARE Working Group. The burden of rare cancers in Europe. *Adv Exp Med Biol* 2010; 686: 285-303
92. Baratti D, Pennacchioli E, Kusamura S, Fiore M, Balestra MR, Colombo C, Mingrone E, **Gronchi A** and Deraco M. Peritoneal Sarcomatosis: is there a subset of patients who may benefit of a cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? *Ann Surg Oncol* 2010; 17(12): 3220-3228
93. Orsenigo M, Brich S, Riva C, Conca E, Bertulli R, Dileo P, **Gronchi A**, Casali PG, Pierotti MA, Tamborini E, Pilotti S. Fluorescence in situ hybridization analysis and immunophenotyping of c-kit/PDGFR α and Bcl-2 expression in gastrointestinal stromal tumors. *Anal Quant Cytol Histol* 2010; 32(4): 225-233
94. Gennaro M, Valeri B, Casalini P, Carcangiu ML, Gronchi A, Conti AR, Agresti R, Greco M. Angiosarcoma of the breast and vascular endothelial growth factor receptor. *Tumori*. 2010; 96(6):930-935.
95. Dileo P, Pricl S, Tamborini E, Negri T, Stacchiotti S, Gronchi A, Posocco P, Laurini E, Coco P, Fumagalli E, Casali PG, Pilotti S. Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study. *Int J Cancer* 2011; 128(4): 983-990
96. Gasparini P, Facchinetti F, Boeri M, Lorenzetto E, Livio A, **Gronchi A**, Ferrari A, Massimino M, Spreafico F, Giangaspero F, Forni M, Maestro R, Alaggio R, Pilotti S, Collini P, Modena P and Sozzi G. Prognostic determinants in Epithelioid Sarcoma. *Eur J Cancer* 2011; 47: 287-295
97. Bonvalot S and **Gronchi A**. ILP and RT: the study that will never be. *Ann Surg Oncol* 2011; 18: 303-305
98. Sanfilippo R, Miceli R, Grosso F, Fiore M, Pennacchioli E, Puma E, Barisella M, Sangalli C, Mariani L, Casali PG and **Gronchi A**. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. *Ann Surg Oncol* 2011; 18: 720-725
99. Berselli M, Coppola S, Colombo C, Pennacchioli E, Fiore M and **Gronchi A**. Morbidity of Left Pancreatectomy when associated with multivisceral resection for Abdominal Mesenchymal Neoplasm. *JOP* 2011; 12(2): 138-144
100. **Gronchi A**, Miceli R, Colombo C, Collini P, Stacchiotti S, Olmi P, Mariani L, Bertulli R, Fiore M and Casali PG. Primary Extremity Soft Tissue Sarcoma: outcome improvement over time at a single institution. *Ann Oncol* 2011; 22(7): 1675-1681
101. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, **Gronchi A**, Casali PG and Pilotti S. Sunitinib in advanced alveolar soft part sarcoma: evidence of direct antitumor effect. *Ann Oncol* 2011; 22(7): 1682-1690
102. Bozzi F, Conca E, Manenti G, Negri T, Brich S, **Gronchi A**, Pierotti MA, Tamborini E, Pilotti S. High CD133 expression levels in gastrointestinal stromal tumors. *Cytometry B Clin Cytom* 2011; 80(B): 238-247
103. **Gronchi A** and Pollock RE. Surgery in retroperitoneal soft tissue sarcoma: a call for a consensus between Europe and North America. *Ann Surg Oncol* 2011; 18: 2107-2110
104. Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, **Gronchi A**, Pilotti S and Casali PG. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. *Int J Cancer* 2011; 129(7): 1761-1772
105. Rossi S, Miceli R, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Toffolatti L, Laurino L, Mariani L, Vinaccia V, Gnocchi C, **Gronchi A**, Casali PG and Dei Tos AP. Natural history of Imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. *Am J Surg Pathol* 2011; 35(11):1646-1656
106. Da Riva L, Bozzi F, Mondellini P, Miccichè F, Fumagalli E, Vaghi E, Tarantino E, Huber V, **Gronchi A**, Tamborini E, Pierotti MA, Pilotti S and Bongarzone I. Proteomic detection of a large amount of SCGF α in the stroma of GISTs after imatinib therapy. *J Transl Med* 2011; 9:158
107. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer*. 2011; 47(17): 2493-2511
108. Visser O, Adolfsson J, Rossi S, et al. Incidence and survival of rare urogenital cancers in Europe. *Eur J Cancer*. 2012; 48(4):456-464
109. Van Dijk BA, Gatta G, Capocaccia R, et al. Rare cancers of the head and neck area in Europe. *Eur J Cancer*. 2012; 48(6):783-796.
110. Mallone S, De Vries E, Guzzo M, et al. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. *Eur J Cancer*. 2012; 48(8):1167-1175
111. Negri T, Brich S, Conca E, Bozzi F, Orsenigo M, Stacchiotti S, Alberghini M, Mauro V, **Gronchi A**, Dusio GF, Pelosi G, Picci P, Casali PG, Pierotti MA, Pilotti S. Receptor Tyrosine Kinase Pathway Analysis Sheds Light on Similarities between Clear Cell Sarcoma and Metastatic Melanoma. *Gene Chromosomes Cancer* 2012; 51(2): 111-126

112. Fiore M, Colombo C; Locati P, Berselli M, Radaelli S, Morosi C, Casali PG and **Gronchi A**. Surgical technique, morbidity and outcome of primary retroperitoneal sarcoma involving inferior vena cava. *Ann Surg Oncol* 2012; 19(2): 511-518.
113. Trama A, Mallone S, Nicolai N, Necchi A, Schaapveld M, Gietema J, Znaor A, Ardanaz E, Berrino F; RARECARE Working Group. Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. *Eur J Cancer*. 2012; 48(2):159-169
114. Faivre J, Trama A, De Angelis R, Elferink M, Siesling S, Audisio R, Bosset JF, Cervantes A, Lepage C; RARECARE Working Group. Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002. *Eur J Cancer*. 2012; 48(10):1417-24
115. Crocetti E, Trama A, Stiller C, Caldarella A, Soffiotti R, Jaal J, Weber DC, Ricardi U, Slowinski J, Brandes A; RARECARE working group. Epidemiology of glial and non-glial brain tumours in Europe. *Eur J Cancer*. 2012; 48(10):1532-42
116. Gatta G, Ferrari A, Stiller CA, Pastore G, Bisogno G, Trama A, Capocaccia R; RARECARE Working Group. Embryonal cancers in Europe. *Eur J Cancer*. 2012; 48(10):1425-33
117. van der Zwan JM, Mallone S, van Dijk B, Bielska-Lasota M, Otter R, Foschi R, Baudin E, Links TP; RARECARE WG. Carcinoma of endocrine organs: results of the RARECARE project. *Eur J Cancer*. 2012;48(13):1923-31
118. **Gronchi A**, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, Hohl RJ, Demetri GD, Le Cesne A, Lardelli P, Perez I, Nieto A, Tercero JC, Alfaro V, Tamborini E and Blay JY. Phase II Clinical Trial of Neoadjuvant Trabectedine in patients with advanced localized myxoid liposarcoma. *Ann Oncol* 2012; 23(3): 771-776
119. **Gronchi A**, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG and Picci P. Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas (STS): a Randomized Clinical Trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS). *J Clin Oncol* 2012; 30(8): 350-356
120. Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, **Gronchi A**, Amore P, Vinaccia V and Casali PG. A Phase II study on imatinib in advanced chordoma. *J Clin Oncol* 2012; 30(9): 914-920
121. **Gronchi A** and Raut CP. The combination of Surgery and Imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. *Ann Surg Oncol* 2012; 19: 1051-1055
122. **Gronchi A**, Miceli R, Colombo C, Stacchiotti S, Collini P, Mariani L, Sangalli C, Radaelli S, Sanfilippo R, Fiore M and Casali PG. Frontline extended surgery is associated with improved survival in retroperitoneal low-intermediate grade soft tissue sarcomas. *Ann Oncol* 2012; 23(4):1067-1073
123. Siesling S, van der Zwan JM, Izarzugaza I, et al. Rare thoracic cancers, including peritoneum mesothelioma. *Eur J Cancer*. 2012; 48(7):949-960
124. Visser O, Trama A, Maynadié M, Stiller C, Marcos-Gragera R, De Angelis R, Mallone S, Tereanu C, Allemani C, Ricardi U, Schouten HC; RARECARE Working Group. Incidence, survival and prevalence of myeloid malignancies in Europe. *Eur J Cancer*. 2012; 48(17):3257-66
125. Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, **Gronchi A**, Corless CL, Goldstein D, Rubin B, Maki RB, Lazar AJ, Lev D, Trent JC and von Mehren M . Non-random association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): Case series of 28 patients. *Ann Oncol* 2012; 23(5): 1335-1340
126. Venturini L, Daidone MG, Motta R, Hoare SF, **Gronchi A**, Folini M, Keith WN, Zaffaroni N. Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. *Neuro-oncology* 2012;14(6):736-744.
127. Collini P, Negri T, Barisella M, Stacchiotti S, Palassini E, Tarantino E, Pastorino U, **Gronchi A**, Casali PG and Pilotti S High-Grade sarcomatous overgrowth in Solitary Fibrous Tumors: a clinical-pathological study of 10 cases. *Am J Surg Pathol* 2012; 36(8):1202-1215
128. Casali PG, Fumagalli E and **Gronchi A**. Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST). *Curr Treat Opt in Oncol* 2012; 13(3):277-284
129. Bonvalot S, Raut CP, Pollock RE , Rutkowski P, Strauss DC, Hayes AJ, Van Coevorden F, Fiore M, Stoeckle E, Hohenberger P and **Gronchi A**. Technical Considerations in Surgery For Retroperitoneal Sarcomas. Position paper from e-SURGE, a masterclass in sarcoma surgery, and EORTC - STBSG. *Ann Surg Oncol* 2012;19(9):2981–2991
130. Colombo C, Ronellenfitch U, Yuxin Z, Rutkowski P, Miceli R, Bylina E, Hohenberger P, Raut CP and **Gronchi A**. Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study. *Ann Surg Oncol* 2012; 19(11):3361-3367
131. Reichardt P, Morosi C, Wardelmann E and **Gronchi A**. Gastrointestinal stromal tumors: Evolving role of the multidisciplinary team approach in management. *Expert Rev Anticancer Ther* 2012; 12(8):1053-1068
132. Colombo C, R Randall L, Andtbacka RHI and **Gronchi A**. A new surgical perspective in soft tissue sarcoma (STS) management: more conservative in ESTS (Extremity Soft Tissue Sarcoma), more extended in RSTS (Retroperitoneal Soft Tissue Sarcoma). *Expert Rev Anticancer Ther* 2012; 12(8):1079-1087
133. Colombo C, Miceli R, Collini P, Radaelli S, Palassini E, Stacchiotti S, Fiore M, Mariani L, Casali PG and **Gronchi A**. Leiomyosarcoma and sarcoma with myogenic differentiation: two different entities or two faces of the same disease? *Cancer* 2012; 118(21): 5349-5357

134. Stacchiotti S, Dagrada P, Morosi C, Negri T, Romanini A, Pilotti S, **Gronchi A** and Casali PG. Extraskeletal Myxoid Chondrosarcoma: tumor response to Sunitinib. *Clin Sarcoma Res* 2012; 2(1): 22.
135. Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Lombart-Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Casali PG and **Gronchi A**. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy: an exploratory analysis on a Phase III trial. *Cancer* 2012; 118(23):5857-5866
136. Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, **Gronchi A**, Dei Tos AP, Morosi C, Messina A, Pilotti S, Casali PG. Sunitinib malate in solitary fibrous tumor (SFT). *Ann Oncol* 2012; 23(12):3171-3179
137. **Gronchi A** and Raut CP. Optimal approach to sporadic desmoid tumor: from radical surgery to observation. Time for a consensus ? *Ann Surg Oncol* 2012; 19:3995-3997
138. ESMO / European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7: vii92-99
139. ESMO / European Sarcoma Network Working Group. Gastrointestinal Stromal Tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7: vii49-55
140. ESMO / European Sarcoma Network Working Group. Bone Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7: vii100-109
141. Jakob J, Mussi C, Ronellenfitsch U, Wardelmann E, Negri T, **Gronchi A** and Hohenberger P. Gastrointestinal Stromal Tumor (GIST) of the rectum: results of surgical and multimodality therapy in the era of Imatinib. *Ann Surg Oncol* 2013; 20(2):586-592.
142. **Gronchi A**. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with GIST. *Eur J Cancer* 2013; 49: 884-892
143. **Gronchi A**, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, Stacchiotti S, Ferrari S, Fiore M and Casali PG. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. *Ann Oncol* 2013; 24(3):817-23
144. **Gronchi A**, Miceli R, Shurell E, Eilber FC, Eilber FR, Anaya DA, Kattan MW, Honoré C, Lev DC, Colombo C, Bonvalot S, Mariani L and Pollock RE. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center datasets. *J Clin Oncol* 2013; 31:1649-1655
145. Stacchiotti S, Libertini M, Negri T, Palassini E, **Gronchi A**, Fatigoni S, Poletti P, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S and Casali PG. Response to chemotherapy of Solitary Fibrous Tumor: a retrospective study. *Eur J Cancer* 2013; 49(10): 2376-2383
146. **Gronchi A** and Pollock RE. Quality of local treatment or biology of the tumor: which are the trump cards for loco-regional control of retroperitoneal sarcoma? *Ann Surg Oncol* 2013; 20: 2111-2113.
147. Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, Casale A, Crippa F, Conca E, Negri T, Palassini E, Marrari A, Palmerini E, Mariani L, **Gronchi A**, Pilotti S, Casali PG. Phase II Study on Lapatinib in advanced EGFR positive Chordoma. *Ann Oncol* 2013; 24: 1931–1936
148. Rutkowski P and **Gronchi A**. Efficacy and economic value of adjuvant Imatinib in GIST. *The Oncologist* 2013; 18: 689-696
149. Duranti L, **Gronchi A**, Stacchiotti S, Fiore M, Casali PG, Collini P, Pelosi G, Galeone C and Pastorino U. Localized thoracic sarcomas: outcome improvement over time at a single institution. *Eur J Cancer* 2013; 49: 2689-2697
150. Baldi G, Stacchiotti S, Mauro V, Dei Tos AP, **Gronchi A**, Pastorino U, Duranti L, Provenzano S, Marrari A, Libertini M, Pilotti S and Casali PG. Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. *Clin Sarcoma Res* 2013; 3(1): 4
151. Stacchiotti S, Crippa F, Messina A, Pilotti S, **Gronchi A**, Blay JY and Casali PG. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. *Clin Sarcoma Res* 2013; 3(1): 8
152. Mattavelli D, Miceli R, Radaelli S, Mattavelli F, Cantù G, Barisella M, Quattrone P, Stacchiotti S, Sangalli C, Casali PG, **Gronchi A** and Fiore M. Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. *Ann Oncol* 2013; 24(8): 2181-2189
153. Rutkowski P, **Gronchi A**, Hohenberger P, Bonvalot S, Schöffski P, Bauer S, Fumagalli E, Nyckowski P, Nguyen BP, Kerst JM, Fiore M, Bylina I, Hoiczky M, Cats A, Casali PG, Le Cesne A, Treckmann J, Stoeckle E, van de Wilt JH, Sleijfer S, Tielens R, van der Graaf W, Verhoef C and van Coevorden F. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST), the EORTC STBSG experience. *Ann Surg Oncol* 2013; 20(9): 2937-2943.
154. **Gronchi A** and Casali PG. Adjuvant Therapy for High-Risk Soft Tissue Sarcoma in the Adult. *Curr Treat Opt in Oncol* 2013; 14(3):415-24
155. Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, Morosi C, Messina A, Libertini M, Palassini E, Cominetti D, Negri T, **Gronchi A**, Pilotti S, Zaffaroni N and Casali PG. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-à-vis temozolomide and antiangiogenics. *Clin Cancer Res* 2013; 19(18):5192-201
156. **Gronchi A**. Extended surgery for retroperitoneal sarcoma: the key to maximizing the potential for cure and survival. *Pro. Oncology (Williston Park)*. 2013; 27(7):640, 642

157. **Gronchi A** and Raut CP. Treatment of localized sarcomas. *Hematol Oncol Clin N Am* 2013; 27:921-938
158. Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le Cesne A, Hartgrink HH, Cleton-Jansen AM, Domont J, Bovée JVMG, Bonvalot S, Lev D, and **Gronchi A**. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent multicenter validation study. *Cancer* 2013; 119:3696-3702.
159. Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollé J, Sanfilippo R, **Gronchi A**, Perrone F, Tamborini E, Pelosi G, Pierotti M, Maestro R, Pricl S and Pilotti S. In vitro and in silico studies of MDM2/MDMX isoforms predict NUTLIN-3A sensitivity in well/de-differentiated liposarcomas. *Lab Invest* 2013; 93(11): 1232-1240
160. Bonvalot S, Ternès N, Fiore M, Bitsakou G, Colombo C, Honoré C, Marrari A, Le Cesne A, Perrone F, Dunant A and **Gronchi A**. Spontaneous regression of primary abdominal wall desmoids: more common than previously thought. *Ann Surg Oncol* 2013; 20(13): 4096-4102
161. Raut CP and **Gronchi A**. Cytoreductive Surgery in Advanced GIST: timing is everything. *Ann Surg Oncol* 2013; 20(13): 4059-4060
162. Stacchiotti S, Dagrada G, Sanfilippo R, Negri T, Vittimberga I, Ferrari S, Grosso F, Apice G, Tricomi M, Colombo C, **Gronchi A**, Dei Tos AP, Pilotti S and Casali PG. Anthracycline-based CT in extraskelatal myxoid chondrosarcoma: a retrospective study. *Clinical Sarcoma Research* 2013; 3: 16
163. Mallone S, De Angelis R, van der Zwan JM, Trama A, Siesling S, Gatta G, Capocaccia; RARE CARE WG. Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project. *Cancer Epidemiol* 2013; 37(6): 850-856
164. Martin-Broto J, Gutierrez AM, Ramos RF, Lopez-Guerrero JA, Ferrari S, Stacchiotti S, Picci P, Calabuig S, Collini P, Gambarotti M, Bague S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martinez-Trufero J, Poveda A, Casali PG, Fernandez A, Lopez-Pousa A and **Gronchi A**. MRP1 overexpression determines poor prognosis in prospectively treated localized high risk soft tissue sarcoma patients of limbs and trunk wall. An ISG/GEIS study. *Mol Cancer Ther* 2014, 13(1):249-59
165. Bozzi F, Manenti G, Conca E, Stacchiotti S, Messina A, Dagrada G, **Gronchi A**, Panizza P, Pierotti M, Tamborini E and Pilotti S. Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. *Neuro-Oncol* 2014; 16(1):72-80
166. **Gronchi A**, De Paoli A, Dani C, Merlo DF; Quagliuolo V, Grignani G, Bertola G, Navarria P, Sangalli C, Buonadonna A, De Sanctis R, Sanfilippo R, Dei Tos AP, Stacchiotti S, Giorello L, Fiore M, Bruzzi P and Casali PG. Preoperative chemo-radiation therapy for localized retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. *Eur J Cancer* 2014; 50:784-792
167. **Gronchi A**, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M and Bonvalot S on behalf of ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm. A position paper from the Italian and the French Sarcoma Group. *Ann Oncol* 2014; 25(3): 578-583
168. Meazza C, Luksch R, Daolio P, Podda M, Luzzati A, **Gronchi A**, Parafioriti A, Gandola L, Collini P, Ferrari A, Casanova M, Terenziani M, Spreafico F, Polastri D, Biassoni V, Schiavello E, Pecori E, Massimino M. Axial Skeletal Osteosarcoma: a 25 year monoinstitutional experience in children and adolescence. *Med Onc* 2014; 31(4): 875
169. Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczkyk M, Cats A, Casali PG, Treckmann J, van Coevorden F, **Gronchi A**. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - analysis of prognostic factors (EORTC-STBSG collaborative study). *Eur J Surg Oncol* 2014; 40(4):412-9
170. Pastorino U, Duranti L, Scannagatta P, Leo F, Piccioni F, Collini P and **Gronchi A**. Thoracopleuropneumectomy with rib-like reconstruction for recurrent thoracic sarcomas. *Ann Surg Oncol* 2014; 21(5):1610-1615
171. Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, Le Cesne A, Gladly RA, Casali PG, Swallow CJ, **Gronchi A**, Bonvalot S and Raut RP. Desmoid-type Fibromatosis and pregnancy. A multi-institutional analysis of recurrence and obstetric risk. *Ann Surg* 2014; 259(5):973-978.
172. Radaelli S, Stacchiotti S, Casali PG and **Gronchi A**. Emerging Therapies for Adult Soft Tissue Sarcomas. *Exp Rev Anticancer Ther* 2014; 14(6):689-704
173. Stacchiotti S, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, **Gronchi A**, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestri R, Pilotti S and Casali PG. Activity of Sunitinib in Extraskelatal Myxoid Chondrosarcoma. *Eur J Cancer* 2014; 50(9): 1657-1664
174. **Gronchi A**, Colombo C and Raut CP. Surgical Management of Localized Soft Tissue Tumors. *Cancer* 2014; 120(17):2638-2648
175. De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada GP, Disciglio V, Sanfilippo R, **Gronchi A**, D'Incalci M, Casali PG, Canevari S, Pierotti MA, Pilotti S. Identification of a gene expression driven progression pathway in Myxoid Liposarcoma. *Oncotarget* 2014; 5(15):5965-5977
176. Radaelli S, Desai A, Hodson J, Colombo C, Roberts K, Gourevitch D and **Gronchi A**. Prognostic factors and outcome of Spermatic Cord Sarcoma. *Ann Surg Oncol* 2014; 21:3557-3563
177. ESMO / European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2014; 25 (Supplement 3): iii102–iii112.

178. ESMO / European Sarcoma Network Working Group. Gastrointestinal Stromal Tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2014; 25 (Supplement 3): iii21–iii26.
179. ESMO / European Sarcoma Network Working Group. Bone Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2014; 25 (Supplement 3): iii113–iii123.
180. Di Giandomenico S, Frapolli R, Bello E, Ubaldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, Casali PG, Grosso F, Sanfilippo R, **Gronchi A**, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JMF and D'Incalci M. Mode of action of trabectedin in myxoid liposarcoma. *Oncogene* 2014; 33(44):5201-5210
181. Tazzari M, Negri T, Rini F, Vergani B, Huber V, Villa A, Dagrada P, Colombo C, Fiore M, **Gronchi A**, Stacchiotti S, Casali PG, Pilotti S, Rivoltini L and Castelli C. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. *Br J Cancer* 2014; 11(7):1350-1362
182. van Broekhoven DLM, Deroose JP, Bonvalot S, **Gronchi A**, Grünhagen DJ, Eggermont AMM and Verhoef C. Isolated limb perfusion by tumor necrosis factor alpha and melphalan in patients with advanced aggressive fibromatosis. *Br J Surg* 2014; 101(13):1674-80.
183. Le Cesne A, Ouali M, Leahy MG, Santoro, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, **Gronchi A**, Hogendoorn PCW, Litiere S, Marreaud S, Blay JY and Van Der Graaf WTA. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. *Ann Oncol* 2014; 25(12):2425-2432
184. Sanfilippo R, Bertulli R, Marrari A, Fumagalli E, Pilotti S, Morosi C, Messina A, Dei Tos AP, **Gronchi A** and Casali PG. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. *Clin Sarcoma Res* 2014; 4:16
185. Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, **Gronchi A**, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG and Zaffaroni N. Preclinical and clinical evidence of activity of Pazopanib in Solitary Fibrous Tumor. *Eur J Cancer* 2014; 50(17):3021-8
186. Morosi C, Stacchiotti S, Marchianò A, Bianchi A, Radaelli S, Sanfilippo R, Colombo C, Richardson C, Collini P, Barisella M, Casali PG, **Gronchi A**, Fiore M. Correlation between Radiological Assessment and Histopathological Diagnosis in Retroperitoneal Tumors: analysis of 291 consecutive patients at a tertiary referral Sarcoma Center. *Eur J Surg Oncol* 2014; 40(12):1662-1670
187. Stiller CA, Trama A, Brwster DH, Verne J, Bouchardy C, Navarro C, Chirlaque MD, Marcos-Gragera R, Visser O, Serraino D, Weiderpass E, Dei Tos AP, Ascoli V; Rarecare Working Group. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. *Cancer Epidemiol* 2014; 38(6):670-678
188. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult. A Consensus Approach from the Trans-Atlantic RPS Working group* *Ann Surg Oncol* 2015; 22(1): 256-263
189. Kasper B, Baumgarten C, Bonvalot S, Haas R, Haller F, Hohenberger P, Moreau G, Van der Graaf W and **Gronchi A**. Management of Sporadic Desmoid-Type Fibromatosis: A European consensus approach based on patients' and professionals' expertise - A Sarcoma Patients EURONET (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC) / Soft Tissue and Bone Sarcoma Group (STBSG) initiative. *Eur J Cancer* 2015; 51(2):127-136
190. Casali PG, Bruzzi P, Bogaerts J and Blay JY on behalf of the Rare Cancers Europe (RCE) Consensus Panel. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. *Ann Oncol* 2015; 26(2):300-306
191. Colombo C, Miceli R, Le Péchoux C, Palassini E., Honoré C, Stacchiotti S, Mir O , Casali PG, Dômont J, Fiore M, Le Cesne A, **Gronchi A** and Bonvalot S. Sporadic Extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. *Eur J Cancer* 2015; 51(2):186-192
192. Palmerini E, Staals EL, Maki RG, Pengo S, Cioffi A, Gambarotti A, Picci P, Daolio PA, Parafioriti A, Morris C, Antonescu CR, **Gronchi A**, Casali PG, Donati DM, Ferrari S, Stacchiotti S. Tenosynovial giant cell tumor/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. *Eur J Cancer* 2015; 51(2):210-217
193. **Gronchi A**. Individualizing the use/non-use of radiation therapy (RT) in soft tissue sarcoma (STS): when abstention is better than care. *J Surg Oncol* 2015; 111(2):133-134
194. **Gronchi A**, Collini P, Miceli R, Renne SL, Dagrada G, Fiore M, Sanfilippo R, Barisella M, Colombo C, Morosi C, Stacchiotti S, Casali PG, Dei Tos AP and Pilotti S. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma. *Am J Surg Pathol* 2015; 39(3):383-93
195. Stacchiotti S, Sommer J, Chordoma Global Consensus Group*. Building a global consensus approach to chordoma: a position paper from the medical and patient community. *Lancet Oncol* 2015;16(2): e71-83
196. Colombo C, Baratti D, Kusamura S, Deraco M and **Gronchi A**. The role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Isolated Perfusion (ILP) Interventions in Sarcoma. *J Surg Oncol* 2015; 111(5):570-579
197. Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, Casanova J, Esler C, Ferrari S, Funovics PT, Gerrand C, Grimer R, **Gronchi A**, Haffner N, Hecker-Nolting S, Höller S, Jeys L, Jutte P, Leithner A, San-Julian M, Thorkildsen J, Vincenzi B, Windhager R, Whelan J. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. *Eur J Cancer* 2015; 51(3):374-81

198. **Gronchi A**, Miceli R, Allard MA, Callegaro D, Le Pécoux C, Fiore M, Honoré C, Sanfilippo R, Coppola S, Stacchiotti S, Terrier P, Casali PG, Le Cesne A, Mariani L, Colombo C and Bonvalot S. Personalizing the approach to Retroperitoneal Soft Tissue Sarcoma: histology specific patterns of failure and post-relapse outcome after primary extended resection. *Ann Surg Oncol* 2015; 22(5):1447-54
199. Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litiere S, Bonnetain F, Dabakuyo TS, Benjamin R, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grossclaude P, **Gronchi A**, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Karup-Hansen A, Le Pechoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut CP, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gorgou-Bourgade S, Mathoulin-Pelissier S. Guidelines for time-to-event endpoint definitions in sarcoma and gastrointestinal stromal tumor (GIST) trials. Results of the DATECAN initiative (Definition for the Assessment of Time-to event Endpoints in CANcer trials). *Ann Oncol* 2015; 26:865–872
200. Callegaro D, Fiore M and **Gronchi A**. Personalizing surgical margins in retroperitoneal sarcoma. *Exp Rev Anticancer Ther* 2015; 15(5):553-67
201. Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, Marzotto A, Boscato E, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Mariani L, Amore P, **Gronchi A**, Casali PG, Maestro R, and Dei Tos AP. KIT, PDGFRA and BRAF mutational spectrum impacts on the natural history of Imatinib-naïve localized GIST: a population-based study. *Am J Surg Pathol* 2015; 39(7):922-930
202. Callegaro D, Miceli R, Brunelli C, Colombo C, Sanfilippo R, Radaelli S, Casali PG, Caraceni A, **Gronchi A**, Fiore M. Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. *Br J Surg* 2015; 102:1079-1087
203. Dagrada GP, Spagnuolo RD, Mauro V, Tamborini E, Cesana L, **Gronchi A**, Stacchiotti S, Pierotti MA, Negri T and Pilotti S. Solitary Fibrous Tumor: loss of chimeric protein expression and genomic instability mark dedifferentiation. *Mod Pathol* 2015; 28(8):1074-1083
204. Hohenberger P, Gorlick R, **Gronchi A**. Collaborations Between SSO and the Connective Tissue Oncology Society (CTOS) Series. *Ann Surg Oncol* 2015; 22(9): 2815-2816
205. Palassini E, Ferrari S, Verderio P, De Paoli A, Martin Broto J, Quagliuolo V, Comandone A, Sangalli C, Palmerini E, Lopez-Pousa A, De Sanctis R, Bottelli S, Libertini M, Picci P, Casali PG and **Gronchi A**. Feasibility of pre-operative chemotherapy + radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk within the ISG/GEIS randomized clinical trial on 3 vs 5 cycles of full-dose epirubicin + ifosfamide. *J Clin Oncol* 2015; 33(31):3628-3634
206. Hindi N, Casali PG, Morosi C, Messina A, Palassini E, Pilotti S, Tamborini E, Radaelli S, **Gronchi A**, Stacchiotti S. Imatinib in advanced chordoma: a retrospective case series analysis. *Eur J Cancer* 2015; 51:2609-14
207. Fiore M, Colombo C, Radaelli S, Callegaro D, Palassini E, Barisella M, Morosi C, Baldi GG, Stacchiotti S, Casali PG, **Gronchi A**. Hormonal manipulation with Toremifene in Sporadic Desmoid-type Fibromatosis. *Eur J Cancer* 2015; 51:2800-2807
208. Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann J, Goldstein D, Martin Broto J, **Gronchi A**, Dei Tos AP, Matreud S, van der Graaf W, Zalberg JR, Litiere S and Blay JY. Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with Imatinib as an adjuvant: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS). *J Clin Oncol* 2015; 33:4276-4283
209. Wardelmann E, Haas RL, Bovée JVMG, Terrier Ph, Lazar A, Messiou C, LePechoux C, Hartmann W, Collin F, Fisher C, Mechtersheimer G, Dei Tos AP, Stacchiotti S, Jones R, **Gronchi A**, Bonvalot S. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. *Eur J Cancer* 2016; 53:84-95
210. Messiou C, Bonvalot S, **Gronchi A**, Vanel D, Meyer M, Robinson P, Morosi C, Bloem JL, Terrier PH, Lazar A, LePechoux C, Wardelman E, Winfield JM, Boulet B, Haas RL. Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on Magnetic Resonance Imaging. *Eur J Cancer* 2016; 56:37-44
211. Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, **Gronchi A**, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, Casali PG. Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP). *Clin Cancer Res* 2016; 22(4):837-46
212. Vienterie M, Litière S, Rizzo E, Marréaud S, Judson I, Gelderblom I, Le Cesne A, Wardelmann E, Messiou C, **Gronchi A**, van der Graaf WTA. Outcome of chemotherapy in advanced synovial sarcoma patients: review of 15 clinical trials from European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG); Setting a new landmark for studies in this subtype. *Eur J Cancer* 2016; 58: 62-72
213. **Gronchi A**, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE and Raut CP. Variability in patterns of recurrence after resection of Primary Retroperitoneal Sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative Transatlantic RPS Working Group. *Ann Surg* 2016; 263(5):1002-1009

214. Raut CP, Miceli R, Strauss DC, Swallow CJ, Hohenberger P, van Coevorden F, Rutkowski P, Fiore M, Callegaro D, Casali PG, Haas RL, Hayes AJ, Honoré C, Cannell AJ, Jakob J, Szacht M, Fairweather M, Pollock RE, Bonvalot S, **Gronchi A**. External Validation of a Multi-Institutional Retroperitoneal Sarcoma Nomogram. *Cancer* 2016; 122(9):1417-24
215. Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Lorusso D, Sabatucci I, Carcangiu ML, Fiore M, **Gronchi A**, Raspagliesi F. Morcellator's port-site metastasis of a uterine smooth muscle tumor of uncertain potential after minimally invasive myomectomy. *J Minim Invasive Gynecol.* 2016; 23(4):647-9.
216. Saponara M, Stacchiotti S and **Gronchi A**. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. *Exp Rev Anticancer Ther* 2016; 16(5):473-484
217. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Le Pechoux C, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Mariani L, Wunder JS, Pollock RE, Casali PG and **Gronchi A**. Development and external validation of two nomograms to predict overall survival and distant metastases after surgical resection of localised soft tissue sarcomas of the extremities: a retrospective analysis. *Lancet Oncol* 2016; 17:671-680
218. Radaelli S, Fiore M, Colombo C, Ford S, Palassini E, Sanfilippo R, Stacchiotti S, Sangalli C, Morosi C, Casali PG and **Gronchi A**. Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. *Surg Oncol* 2016; 25(3):125-131
219. **Gronchi A**, Guadagnolo BA, Erinjeri JP. Local Ablative Therapies to Metastatic Soft Tissue Sarcoma. *Am Soc Clin Oncol Educ Book.* 2016;35:e566-e575
220. Radaelli S, Stacchiotti S, Ruggieri P, Donati D, Casali PG, Palmerini E, Collini P, Gambarotti M, Porcu L, Boriani S, **Gronchi A**, Picci P. Sacral Chordoma: Long-Term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers. *Spine* 2016; 41(12):1049-1057
221. Ford S and **Gronchi A**. Indications for Surgery in Advanced/Metastatic GIST. *Eur J Cancer* 2016; 63: 154-167.
222. Grünwald V, Young R, Messiou C, Lia M, Wardelmann E, van der Graaf W, **Gronchi A**, Judson I for the EORTC STBSG. Absence of progression, not extent of remission tumour shrinkage defines prognosis in soft tissue sarcoma – an analysis of the EORTC 62012 study of the EORTC STBSG. *Eur J Cancer* 2016; 64:44-51
223. Ray-Coquard I, Litiere S, Rizzo E, Blay JY, Casali PG, Judson I, Krarup Hansen A, Lindner LH, Dei Tos AP, Gelderblom H, Marreaud S, Rutkowski P, Hohenberger P, **Gronchi A**, Van der Graaf WT. Impact of chemotherapy in Uterine Sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other Soft Tissue Sarcoma (STS) patients treated with first line chemotherapy. *Gynecol Oncol* 2016;142(1):95-101
224. **Gronchi A**, Haas RL and Bonvalot S. Cancer Registries and randomized clinical trials in rare tumors: at the 2 extreme of daily clinical practice. *Eur J Cancer* 2016; 64:113-115
225. Meazza C, Perrone F, Belfiore A, Busico A, Settanni G, Paielli N, Cesana L, Ferrari A, Chiaravalli S, **Gronchi A**, Colombo C, Pilotti S, Massimino A. AKT1 and BRAF mutations in pediatric aggressive fibromatosis. *Cancer Med* 2016; 5(6):1204-13
226. Pasquali S, **Gronchi A**, Strauss D, Bonvalot S, Jeys L, Stacchiotti S, Hayes A, Honoré C, Collini P, Renne SL, Alexander N, Grimer RJ, Callegaro D, Sumathi VP, GourevitchD, Desai A. Resectable extrapleural and extrameningeal Solitary Fibrous Tumor: a multi centre prognostic study. *Eur J Surg Oncol* 2016; 42:1064-1070
227. Eastley N, McCulloch T, Esler C, Hennig I, Fairbairn J, **Gronchi A** and Ashford R. Extra-abdominal Desmoids Fibromatosis: a review of management, current guidance and unanswered questions. *Eur J Surg Oncol* 2016; 42:1071-1083
228. Stacchiotti A, Provenzano S, Dagrada GP, Negri T, Brich S, Basso U, Brunelio A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, **Gronchi A**, Dei Tos AP, Crippa F, Morosi C, Pilotti S and Casali PG. Sirolimus in advanced hemangioendothelioma: a retrospective case series analysis from the Italian Rare Cancer Network database. *Ann Surg Oncol* 2016; 23(9):2735-44
229. van Broekhoven DL, Grünhagenl DJ, van Dalen T, van Coevorden F, Bonenkamp HJ, Been LB, Bemelmans MH, Dijkstra SD, Colombo C, **Gronchi A**, Verhoef C. Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention. *BMC Cancer.* 2016;16(1):686
230. Fiore M, MacNeill A, **Gronchi A**, Colombo C. Desmoid-type Fibromatosis: evolving treatment standards. *Surg Oncol Clin N Am* 2016; 25:803-826
231. Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult. A Consensus Approach from the Trans-Atlantic RPS Working group*. *Ann Surg Oncol* 2016; 23:3531-3540.
232. Stacchiotti S, Astolfi A, **Gronchi A**, Fontana A, Pantaleo MA, Negri T, Brenca M, Tazzari M, Urbini M, Indio V, Colombo C, Radaelli S, Brich S, Dei Tos AP, Casali PG, Castelli C, Dagrada GP, Pilotti S, Maestro R. Evolution of Dermatofibrosarcoma protuberans (DFSP) to DFSP-derived fibrosarcoma (FS-DFSP): an event marked by epithelial mesenchymal transition-like process and 22q loss. *Mol Cancer Res* 2016; 14(9):820-9
233. Tseng WW, Pollock RE and **Gronchi A**. The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG): "Red wine or white"? *Ann Surg Oncol* 2016; 23(13):4418-4420

234. **Gronchi A**, Delrio P, Quagliuolo V, Sandrucci S. The Italian Society of Surgical Oncology (SICO) survey on the minimum requirements of rare cancers referral centers. *Updates Surg* 2016; 68(4):321-323
235. Belli F, **Gronchi A**, Corbellini C, Milione M and Leo E. Abdominosacral resection for locally recurring rectal cancer. *World J Gastrointest Surg* 2016; 8(12): 770-778
236. **Gronchi A**, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch S, Dei Tos AP, Collini P, Cruz Jurado J, De Paoli A, Donati DM, Poveda A, Quagliuolo A, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, Casali PG and Picci P. Short, Full-Dose Adjuvant Chemotherapy (CT) in High-Risk Adult Soft Tissue Sarcomas (STS): Long term Follow-Up of a Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. *Ann Oncol* 2016; 27(12):2283-2288
237. Saponara M, Stacchiotti S, Casali PG and **Gronchi A**. (Neo)adjuvant treatment in localized soft tissue sarcoma (STS): the unsolved affair. *Eur J Cancer* 2017; 70:1-11
238. **Gronchi A**, Maki RG, Jones RL. Treatment of soft tissue sarcoma: a focus on earlier stages. *Future Oncol.* 2017; 13(1s):13-21
239. Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Boccone P, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf W, Touati N, Litière S, Marreud S, **Gronchi A**, Kasper B. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. *Acta Oncol* 2017; 56(1):88-92
240. Gasparotto D, Rossi S, Polano M, Tamborini E, Lorenzetto E, Sbaraglia M, Mondello A, Massani M, Lamon S, Bracci R, Mandolesi A, Frate E, Stanzial F, Agaj J, Mazzoleni G, **Gronchi A**, Dei Tos AP and Maestro R. Quadruple-negative GIST is a sentinel for unrecognized Neurofibromatosis Type 1 syndrome. *Clin Cancer Res* 2017; 23(1):273-282
241. Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, Stacchiotti S, Dagrada GP, Casali PG, **Gronchi A**, Astolfi A, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C. Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment. *J Invest Dermatol* 2017; 137:484-493
242. Longhi A, Bielack SS, Grimer R, Whelan J, Windhager R, Leithner A, **Gronchi A**, Biau D, Jutte P, Krieg AH, Klenke FM, Grignani G, Donati DM, Capanna R, Casanova J, Gerrand C, Bisogno G, Hecker-Nolting S, De Lisa M, D'Ambrosio L, Willegger M, Scocciati G and Ferrari S. Extraskelatal osteosarcoma: a European Musculoskeletal Oncology Society (EMSOS) study on 266 patients. *Eur J Cancer* 2017;74:9-16
243. Janssen ML, van Broekhoven DLM, Cates JMM, Brammer WM, Nuyttens JJME, **Gronchi A**, Baumert BG, Salas S, Bonvalot S, Ihalainen HR, Grunhagen DJ, Verhoef C. The Influence of Adjuvant Radiotherapy and Surgical Margin on Local Control After Resection of Sporadic Desmoid-type Fibromatosis: A Systematic Review and Meta-Analysis. *Br J Surg* 2017;104(4):347-357
244. Saponara M, Stacchiotti S and **Gronchi A**. Pharmacological therapies for Liposarcoma. *Exp Rev Clin Pharmacol* 2017;10(4):361-377
245. Stacchiotti S, M. Saponara, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, **Gronchi A**, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N. Patient-derived solitary fibrous tumor xenografts predict high sensitivity to Doxorubicin/Dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumor. *Eur J Cancer* 2017;76:84-92.
246. Sandrucci S, Trama A, Quagliuolo V, **Gronchi A**. Accreditation for centers of sarcoma surgery. *Updates Surg* 2017;69(1):1-7
247. Fiore M, Raut CP and **Gronchi A**. Are We Allowed to Limit Surgical Aggressiveness With Small Rectal Gastrointestinal Stromal Tumors? *Ann Surg Oncol* 2017; 24:1153-1156
248. Delhorme JB, Fontana A, Levy A, Terrier P, Fiore M, Tzanis D, Callegaro D, Dratwa C, **Gronchi A**, Bonvalot S. Renal Angiomyolipomas: at Least Two Diseases. A Series of Patients Treated at Two European Institutions. *Eur J Surg Oncol* 2017; 43:831-836
249. Palassini E, Frezza AM, Mariani L, Lalli L, Colombo C, Fiore M, Messina A, Casale A, Morosi C, Collini P, Stacchiotti S, Casali PG, **Gronchi A**. Long-term efficacy of methotrexate plus vinblastine/vinorelbine in large series of patients affected by desmoid-type fibromatosis. *Cancer J* 2017; 23: 86–91
250. Pantaleo MA, Urbini M, Indio V, Ravegnini G, Nannini M, De Luca M, Tarantino G, Angelini S, **Gronchi A**, Vincenzi B, Grignani G, Colombo C, Fumagalli E, Gatto L, Saponara M, Ianni M, Paterini P, Santini D, Pirini MG, Ceccarelli C, Altissimi A, Gruppioni E, Renne SL, Collini P, Stacchiotti S, Brandi G, Casali PG, Pinna AD, Astolfi A, Biasco G. Genome-wide Analyses Identifies MEN1 and MAX Mutations and a Neuroendocrine-like Molecular Heterogeneity in Quadruple WT GIST. *Mol Cancer Res* 2017; 15(5):553-562
251. Pasquali S and **Gronchi A**. Retroperitoneal Liposarcoma: an aggressive strategy to maximize disease control. *Int J Radiat Oncol Biol Phys* 2017; 98:273-274
252. Urbini M , Astolfi A, Pantaleo MA, Serravalle S , Dei Tos AP , Picci P , Indio V , Sbaraglia M , Benini S , Righi A , Gambarotti M , **Gronchi A**, Colombo C , Dagrada GP, Pilotti S , Maestro R , Polano M, Saponara M , Tarantino G , Pession G, Biasco G, Casali PG, Stacchiotti S. HSPA8 as a novel fusion partner of NR4A3 in extraskelatal myxoid chondrosarcoma. *Gene Chrom Cancer* 2017; 56(7):582-586
253. **Gronchi A**; Ferrari S Quagliuolo V; Martin Broto J; Lopez Pousa A; Grignani G; Basso U; Blay JY; Tendero O; Diaz Beveridge R; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P and Casali PG. Neoadjuvant Chemotherapy in High-risk Soft Tissue Sarcomas: A Randomized Clinical Trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG) and the Polish Sarcoma Group (PSG). *Lancet Oncol* 2017;18:812-822

254. Casali PG, Zalcborg J, Le Cesne A, Reichardt P, Blay JY, Lindner L, Judson I, Schöffski P, Bauer J, Italiano A, Grünwald V, Lopez Pousa A, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn PCW, Litière S, Marreaud S, Van der Graaf W, **Gronchi A**, Verweij J, on behalf of EORTC STBSG, ISG, AGITG. Ten-year progression-free and overall survival in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST). Long-term analysis of the EORTC, ISG, AGITG intergroup Phase III randomized trial on imatinib at two dose levels. *J Clin Oncol* 2017; 35:1713-1720
255. Callegaro D, Miceli R and **Gronchi A**. Sarcoma nomograms: a light over the darkness. *Oncoscience* 2017; 4(3-4):15-16
256. Young R, Litiere S, Lia M, Hogendoorn PCW, Fisher C, Mechttersheimer G, Daugaard S, Sciot R, Collin F, Messiou C, Grunwald V, **Gronchi A**, van der Graaf W, Wardelmann E, Judson I. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. *Acta Oncol* 2017; 56(7):1013-1020
257. MacNeill AJ, Miceli R, Strauss DC, Bonvalot S, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE, Raut CP, **Gronchi A** and Swallow CJ. Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: a report from the Trans-Atlantic RPS Working Group (TARPSWG). *Cancer* 2017; 123(11):1971-1978
258. Stacchiotti S, **Gronchi A**, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, P. Gardner A, Gelderblom H., Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krenkli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, LA Vleggeert-Lankamp C, Casali PG, and Sommer J. Best practices for the Management of Local-regional Recurrent Chordoma. A Position Paper by the Chordoma Global Consensus Group. *Ann Oncol* 2017; 28:1230-1242
259. Frezza AM, Stacchiotti S and **Gronchi A**. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. *BMC Medicine* 2017; 15:109
260. Pasquali S, Palassini E, Stacchiotti S, Casali PG and **Gronchi A**. Neoadjuvant treatment: a novel standard? *Curr Opin Oncol* 2017; 29:253-259
261. Pasquali S and **Gronchi A**. Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. *Ther Adv Med Oncol* 2017; 9(6):415-429
262. Ford SJ, Almond LM and **Gronchi A**. An update on non-extremity soft tissue sarcomas. *Clin Oncol* 2017; 29:516-527
263. Callegaro D, Miceli R, Mariani L, Raut CP and **Gronchi A**. Soft Tissue Sarcoma Nomograms and their Incorporation into Practice. *Cancer in* 2017;123:2802-2820
264. Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Onetti Muda A, **Gronchi A**, Casali PG, Dei Tos AP and Tonini G. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. *Br J Cancer* 2017; 117:340-346
265. Tseng WW and **Gronchi A**. Surgery for Recurrence in Retroperitoneal Leiomyosarcoma: Is it All About Selection? *J Surg Oncol* 2017; 16(3):267-268.
266. Frezza AM, Stacchiotti S and **Gronchi A**. Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting. *BMC Med* 2017; 15(1):160
267. Colia V, Fiore M, Provenzano S, Fumagalli E, Bertulli R, Morosi C, Dei Tos AP, Barisella M, **Gronchi A**, Casali PG and Sanfilippo R. Activity of anthracycline and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma. *Clin Sarcoma Res* 2017; 7:16
268. Urbini M, Astolfi A, Indio V, Tarantino G, Serravalle S, Saponara M, Nannini M, **Gronchi A**, Fiore M, Maestro R, Brenca M, Dei Tos AP, Dagrada GP, Negri T, Pilotti S, Casali PG, Biasco G, Pession A, Stacchiotti S, Pantaleo MA. Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. *Oncotarget* 2017; 8(36):60036-60045
269. Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, Hohenberger P, Penel N, Messiou C, van der Graaf WT, **Gronchi A** on behalf of the Desmoid Working Group. An update on the management of sporadic Desmoid-Type Fibromatosis: a European consensus initiative between Sarcoma Patients Euronet (SPAEN) and European Organisation for Research and Treatment of Cancer (EORTC) / Soft Tissue and Bone Sarcoma Group (STBSG). *Ann Oncol* 2017; 28:2399-2408
270. Colia V, Fumagalli E, Provenzano S, Bertulli R, Stacchiotti S, Morosi C, Collini P, **Gronchi A**, Casali PG and Sanfilippo R. High-dose Ifosfamide chemotherapy in a series of patients affected by myxoid liposarcoma. *Sarcoma* 2017; 2017:3739159
271. De Sanctis R, Giordano L, Colombo C, De Paoli A, Navarria P, Sangalli C, Buonadonna A, Sanfilippo R, Bertola G, Fiore M, Marrari A, Navarria F, Bertuzzi A, Casali PG, Basso S, Santoro A, Quagliuolo V, **Gronchi A**. Long-term follow-up and post-relapse outcome of patients with localized retroperitoneal sarcoma treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STs) Protocol 0303. *Ann Surg Oncol* 2017; 24:3872-3879

272. Colombo C, Belfiore A, Paielli N, De Cecco L, Canevari S, Laurini E, Fermeglia M, Pricl S, Verderio P, Bottelli S, Fiore M, Stacchiotti S, Palassini E, **Gronchi A**, Pilotti S, Perrone F. β -catenin in Desmoid-Type Fibromatosis: deep insights on the role of T41A and S45F mutations on protein structure and gene expression. *Mol Oncol* 2017; 11(11):1495-1507
273. Pastorino U, Scannagatta P, Girotti P, Rolli L, **Gronchi A**. Long-term results of thoraco-pleuro-pneumectomy (TPP) for recurrent thoracic sarcomas. *Ann Surg Oncol* 2017;24(Suppl 3):551-554
274. Strauss DC, Renne SL and **Gronchi A**. Adjacent, Adherent, Invaded: a spectrum of biological aggressiveness rather than a rationale for selecting organ resection in surgery of primary retroperitoneal sarcomas. *Ann Surg Oncol* 2018;25(1):13-16
275. Rossi S, Gasparotto D, Cacciatori M, Sbaraglia M, Mondello A, Polano M, Mandolesi A, **Gronchi A**, Reuss DE, von Deimling A, Maestro R and Dei Tos AP. Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs. *Mod Pathol* 2018;31(1):160-168
276. Haas RL, **Gronchi A**, van de Sande MAJ, Baldini EH, Gelderblom H, Messiou C, Wardelmann E, Le Cesne A. Perioperative management of extremity soft tissue sarcomas. *J Clin Oncol* 2018;36(2):118-124.
277. Albertsmeier M, Rauch A, Roeder F, Hasenhütl S, Pratschke S, Kirschneck M, **Gronchi A**, Jebesen NL, Cassier PA, Sargos P, Belka C, Lindner LH, Werner J, Angele MK. External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma – a Systematic Review and Meta-Analysis. *Ann Surg Oncol* 2018; 25(3):754-767
278. Corino VDA, Montin E, Messina A, Casali PG, **Gronchi A**, Marchiano' A, Mainardi LT. Radiomic analysis of soft tissues sarcomas can distinguish intermediate from high-grade lesions. *J Magn Reson Imaging* 2018;47:829–840
279. Pasquali S, Colombo C, Pizzamiglio S, Verderio P, Callegaro D, Stacchiotti S, Martin Broto J, Lopez-Pousa A, Ferrari S; Poveda A, De Paoli A, Quagliuolo V, Cruz Jurado J, Comandone A, Grignani G, De Sanctis R, Palassini E, Llomboart-Bosch A, Dei Tos AP, Casali PG, Picci P, and **Gronchi A**. High-risk soft tissue sarcomas treated with perioperative chemotherapy: improving prognostic classification in a randomised clinical trial. *Eur J Cancer* 2018; 93:28-36
280. Tseng WW, Pollock RE. **Gronchi A**. Retroperitoneal Sarcomas: Big tumors that Involve More than Just “Getting It Out”. *J Surg Oncol* 2018; 117:5-6
281. Tseng WW, Pollock RE. **Gronchi A**. Historical Perspectives and Future Directions in the Surgical Management of Retroperitoneal Sarcoma. *J Surg Oncol* 2018; 117:7-11
282. Paderno A, **Gronchi A** and Piazza C. Synovial Sarcoma of the upper aero-digestive tract: is there a role for conservative surgery. *Curr Opin Otolaryngol Head Neck Surg* 2018; 26(2):94-101
283. Zanotti S, Kapetis D, Gibertini S, Salerno F, Ciusani E, Colombo C, **Gronchi A**, Morandi L, Mantegazza R, Molteni F, Mora M. Botulinum toxin type A affects the transcriptome of cell cultures derived from muscle biopsies of controls and spastic patients. *Toxicol in Vitro* 2018; 50:124-136
284. Verschoor AJ, Litiere S, Marreaud S, Judson I, Toulmonde M, Wardelmann E, van der Graaf WT, Le Cesne A, **Gronchi A**, Gelderblom H. Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study. *Eur J Cancer* 2018; 94:187-198
285. MacNeill AJ, **Gronchi A**, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE, Barretta F, Raut CP and Strauss DC. Title: Post-operative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the Transatlantic RPS Working Group (TARPSWG). *Ann Surg* 2018; 267(5):959-964
286. Almond LM, **Gronchi A**, Strauss DC, Jafri M, Ford S, Desai A. Neoadjuvant and Adjuvant Strategies in Retroperitoneal Sarcoma. *Eur J Surg Oncol* 2018; 44:571-579
287. Kasper B, Lecointe-Artznerb E, Waito S, Boldond S, Wilson R, **Gronchi A**, Valverde C, Eriksson M, Dumont S, Drove N, Kanli A, Wartenberg M. Working to improve the management of sarcoma patients across Europe: a policy checklist. *BMC Cancer* 2018; 18(1):424
288. Management of metastatic retroperitoneal sarcoma: a consensus approach from the Transatlantic Retroperitoneal Sarcoma Working Group (TARPSWG). *Ann Oncol* 2018; 29(4):857-871
289. Fiore M, Ford S, Callegaro D, Sangalli C, Colombo C, Radaelli S, Frezza AM, Renne SL, Casali PG, **Gronchi A**. Adequate local control in high risk soft tissue sarcoma of the extremity treated with surgery alone at a reference center: should radiotherapy still be a standard? *Ann Surg Oncol* 2018; 25(6):1536-1543
290. Lindner LH, Litière S, Sleijfer S, Benson C, Italiano A, Kasper B, Messiou C, Gelderblom H, Wardelmann E, Le Cesne A, Blay JY, Marreaud S, Hindi N, Desar IME, **Gronchi A**, van der Graaf WTA. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy. An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). *Int J Cancer* 2018;42(12):2610-2620
291. Benna C, Simioni A, Pasquali S, De Boni D, Rajendran S, Spiro G, Colombo C, Virgone C, Dubois S, **Gronchi A**, Rossi CR, Mocellin S. Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis. *Oncotarget* 2018;9(26):18607-18626
292. Italiano A, Touati N, Litière S, Collin F, Pourquier P, **Gronchi A**. Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial. *Cancer Med* 2018; 7(5):1575-1577

293. Jung E, Fiore M, **Gronchi A**, Grignol V, Pollock RE, Chopra, S, Chong SS, Hamilton AS, Tseng WW. Second Primary Malignancies in Patients with Well differentiated / Dedifferentiated Liposarcoma. *Anticancer Res* 2018; 38(6):3535-3542
294. Issels RD, Lindner LH, Verweij J, Wessalowski R, Reichardt P, Wust P, Ghadjar P, Hohenberger P, Angele M, Salat C., Vujaskovic Z, Daugaard S, Mella O, Mansmann U., Dürr HR, Knösel T, Abdel-Rahman S., Schmidt M, Hiddemann W, Jauch KW, Belka K, and **Gronchi A**, for the European Organization for the Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group and the European Society for Hyperthermic Oncology. Neoadjuvant Chemotherapy Plus Regional Hyperthermia and Long-term Outcomes among Patients with Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. *Jama Oncol* 2018;4(4):483-492
295. Tseng WW, Tsao-Wei DD, Callegaro D, Grignani G, D'Ambrosio L, Bonvalot S, Ethun CG, Cardona K, Mullen JT, Canter RJ, Mullinax JE, Gonzalez RJ, van Coevorden F, Albertsmeier M, Dhanireddy KK, Renne SL, **Gronchi A**. Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. *Eur J Surg Oncol* 2018 Jun;44(6):810-815
296. Touati N, Schöffski P, Litière S, Judson I, Sleijfer S, van der Graaf WT, Italiano A, Isambert N, Gil T, Blay JY, Stark D, Brodowicz T, Marréaud S, **Gronchi A**. EORTC Soft Tissue and Bone Sarcoma Group (STBSG) experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: clinical profile and response to systemic therapy. *Clin Oncol* 2018; 30:448-454
297. **Gronchi A** Crago A and Raut CP. Minimally Invasive Surgery for Retroperitoneal Sarcoma: Just Because We Can Does Not Mean We Should. *Ann Surg Oncol* 2018; 25:2129-2131
298. Tattersall HL and **Gronchi A**. Surgical Resection as an Adjuvant to Tyrosine Kinase Inhibitors in Metastatic GIST: Association or Causation? / Are we any closer to an answer? *Eur J Surg Oncol* 2018; 44:1287-1288
299. Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, Palmerini E, Casali PG, **Gronchi A**, Parry M, Campanacci DA, Scoccianti G, Wagrodzki M, Ferrari S, Dijkstra S, Pieńkowski A, Grimer R. Denosumab treatment of inoperable or locally advanced Giant Cell Tumor of Bone - multicenter analysis outside clinical trial. *Eur J Surg Oncol* 2018; 44:1384-1390
300. **Gronchi A**. Towards the standard use of (Neo)adjuvant chemotherapy in selected localized soft tissue sarcoma at high risk of relapse: are we finally getting there? *Eur J Cancer* 2018; 101:251-253
301. Urbini M, Indio V, Astolfi A, Tarantino G, Renne SL, Pilotti S, Dei Tos AP, Maestro R, Collini P, Nannini M, Saponara M, Murrone L, Dagrada P, Colombo C, **Gronchi A**. Pession A, Casali PG, Stacchiotti S, Pantaleo M. Identification of an actionable mutation of Kit in a case of extraskeletal myxoid chondrosarcoma. *Int J Mol Science* 2018 Jun 23;19(7). pii: E1855
302. Levy A, Bonvalot S, Callegaro D, Botticella A, Le Cesne A, **Gronchi A** and Le Pechoux C. Consistent margin status reporting in soft tissue sarcoma essential to establish risk adapted strategies integrating biology and histotype in perioperative treatments. *J Clin Oncol* 2018; 36(22):2357-2358
303. Colombo C, Urbini M, Astolfi A, Collini P, Belfiore A, Paielli N, Perrone F, Indio V, Tarantino G, Palassini E, Fiore M, Stacchiotti S, Pantaleo MA, **Gronchi A**. Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis. *Gene Chrom Cancer* 2018; 57(10):495-503
304. Sleijfer S, Rizzo E, Litière S, Mathijssen RHJ, Judson IR, Gelderblom H, Van Der Graaf WTA, **Gronchi A**. Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-Soft Tissue and Bone Sarcoma Group database. *Acta Oncol* 2018; 57(8):1117-1126
305. Frezza AM, Lee ATJ, Nizri E, Sbaraglia M, Jones RL, **Gronchi A**, Dei Tos AP, Casali PG. 2018 ESMO Sarcoma and GIST Symposium: 'take-home messages' in soft tissue sarcoma. *ESMO Open* 2018 3(4):e000390
306. Tattersall HL, Callegaro D, Ford SJ, **Gronchi A**. Staging, Nomograms and Other Predictive Tools in Retroperitoneal Soft Tissue Sarcoma. *Chin Clin Oncol* 2018; 7(4):36
307. Wang J, Grignol VP, **Gronchi A**, Luo CH, Pollock RE, Tseng WW. Surgical Management of Retroperitoneal Sarcoma and Opportunities for Global Collaboration. *Chin Clin Oncol* 2018; 7(4):39
308. Dumitra S and **Gronchi A**. The diagnosis and management of retroperitoneal sarcoma. *Oncology* 2018; 32(9):464-469
309. Frezza AM; Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahma M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desar IME, Benjamin RSE, Blay JY, Martin Broto J, Casali PG, Gelderblom H, Grignani G, **Gronchi A**, Sundby Hall K, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Terrier P, Picci P, Ranchere, D, Renne SL, Sbaraglia M, Thway, K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S. Anthracycline, gemcitabine and pazopanib in epithelioid sarcoma: results of a retrospective multi-institutional case series. *Jama Oncol* 2018; 4(9):e180219
310. **Gronchi A** and Jones RL. The value of neoadjuvant chemotherapy in localized high risk soft tissue sarcoma of the extremities and trunk. *JAMA Oncol* 2018; 4(9):1167-1168
311. Casali PG, Bielack S, Abecassis N, Haro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Brennan B, Broto JM, Brugieres L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, **Gronchi A**, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY, on behalf of the ESMO Guidelines Committee, PaedCan and ERN

EURACAN. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018; 29 (Supplement 4): iv79–iv95

312. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, **Gronchi A**, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkovski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018; 29 (Supplement 4): iv68–iv78
313. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, **Gronchi A**, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkovski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018; 29 (Supplement 4): iv51–iv67
314. Younger E, Litière S, Le Cesne A, Mir O, Gelderblom H, Italiano A, Marreaud S, Jones RL, **Gronchi A**, van der Graaf WT. Outcomes of elderly advanced soft tissue sarcoma patients treated with first-line chemotherapy: a pooled analysis of twelve EORTC Soft Tissue and Bone Sarcoma Group trials. *The Oncologist* 2018; 23(10):1250-1259
315. Savina M, Litière S, Italiano A, Burzykowski T, Bonnetain F, Gourgou S, Rondeau V, Blay JY, Cousin S, Duffaud F, Gelderblom H, **Gronchi A**, Judson I, Le Cesne A, Lorigan P, Maurel J, van der Graaf W, Verweij J, Mathoulin-Pelissier S, Bellera C. Surrogate endpoints in advanced sarcoma trials: a meta-analysis. *Oncotarget* 2018; 9(77):34617-34627
316. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Le Pèchoux C, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Catton C, Casali PG, 10, Wunder JS, **Gronchi A**. Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centers. *Eur J Cancer* 2018; 105:19-27
317. Stacchiotti S, Morosi C, Lo Vullo S, Casale A, Palassini E, Frezza AM, Dinoi G, Messina A, **Gronchi A**, Morelli D, Cavalleri A, Venturelli E, Pilotti S, Collini P, Brich S, Tamborini E, Mariani L, Casali PG. Imatinib in combination with everolimus in patients with progressing advanced chordoma: a Phase 2 clinical study. *Cancer* 2018; 124(20):4056-4063
318. Raut CP, Bonvalot S and **Gronchi A**. A Call to Action: Why Sarcoma Surgery Needs to be Centralized. *Cancer* 2018; 124(23):4452-4454
319. Giannini L, Incandela F, Fiore M, **Gronchi A**, Stacchiotti S, Sangalli C and Piazza C. Radiation Induced Sarcoma of the Head and Neck: a review of the literature. *Front Oncol* 2018 Oct 17;8:449
320. Fiore M and **Gronchi A**. ASO Author Reflections: Evolving Concepts for Radiation Therapy in Extremity and Trunk Soft Tissue Sarcoma. *Ann Surg Oncol* 2018; 25(Suppl 3):942-943
321. Stacchiotti S, Simeone N, Lo Vullo S, Morosi C, Greco FG, **Gronchi A**, Barisella M, Collini P, Zaffaroni N, Dagrada GP, Frezza AM, Mariani L, Casali PG. Activity of axitinib in progressive advanced solitary fibrous tumor: results from an exploratory, investigator-driven Phase 2 clinical study. *Eur J Cancer* 2019; 106:225-233
322. Gonzato O and **Gronchi A**. The evolving role of patient advocates in rare cancers: opportunities and challenges. *Expert Rev Pharmacoecon Outcomes Res* 2019; 19(1):1-3
323. Pasquali S; Bonvalot S; Tzanis D; Casali PG; Trama A; **Gronchi A**. Treatment challenges in and outside a network setting: soft tissue sarcomas. *Eur J Surg Oncol* 2019; 45:31-39
324. Pasquali S, Pizzamiglio S, Touati N, Litière S, Marreaud S, Kasper B, Gelderblom H, Stacchiotti S, Judson I, Dei Tos AP, Verderio P, Casali PG, Woll PJ and **Gronchi A**, on behalf of the EORTC – Soft Tissue and Bone Sarcoma Group. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomized trial. *Eur J Cancer* 2019; 109:51-60
325. Nizri E, Fiore M, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, Morosi C, Stacchiotti S, Casali PG, **Gronchi A**. Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas achieves comparable oncological outcomes- a propensity score analysis. *J Surg Oncol* 2019; 119:318-323
326. Pastorino U, Morelli D, Leuzzi G, Rolli aL Suatoni P, Taverna F, Bertocchi E, Boeri M, Sozzi G, Cantarutti A, Corrao G, **Gronchi A**. Baseline and postoperative C-reactive protein levels predict long-term survival after lung metastasectomy. *Ann Surg Oncol* 2019; 26(3):869-875
327. Ferraris M, Callegaro D, Barretta F, Fiore M, Radaelli S, Stacchiotti S, Miceli R, Socrate AM, Locati P, **Gronchi A**. Outcome of ilio caval resection and reconstruction for retroperitoneal sarcoma. *J Vasc Surg Venous Lymphat Disord* in press

328. Almond LM, Tattersall H, Hodson J, Cascella T, Barisella M, Marchianò A, Greco G, Desai A, Ford SJ, **Gronchi A**, Fiore M, Morosi C. Diagnostic Accuracy of Percutaneous Biopsy in Retroperitoneal Sarcoma. *Br J Surg* in press
329. Haas RL, Bonvalot S, Miceli R, Strauss DC, Swallow CJ, Hohenberger P, van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Gladdy R, Jakob J, Szacht M, Fiore M, Chung PW, van Houdt WJ, Raut CP, **Gronchi A**. Radiation Therapy for Retroperitoneal Liposarcoma – a report from TARPSWG. *Cancer* in press
330. **Gronchi A** and Jones RL. Treatment of Desmoid Tumor in 2019. *JAMA Oncol* in press
331. Mir O, Touati N, Lia M, Litière S, Le Cesne A, Sleijfer S, Blay JY, Leahy M, Young R, Mathijssen R, Van Erp NP, Gelderblom AJ, Van der Graaf WT, **Gronchi A**. Impact of concomitant administration of gastric acid suppressive agents and pazopanib on outcomes in soft tissue sarcoma patients treated within EORTC 62043/62072 trials. *Clin Cancer Res* in press
332. Fucà G, Hindi N, Ray-Coquard I, Colia V, Dei Tos AP, Martin-Broto J, Brahmi M, Collini P, Lorusso D, Raspagliesi F, Pantaleo MA, Vincenzi B, Fumagalli E, **Gronchi A**, Casali PG, Sanfilippo R. Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. *The Oncologist* in press
333. Raut CP, Callegaro D, Miceli R, Barretta F, Rutkowski P, Blay JY, Lahat G, Strauss DC, Gonzalez R, Ahuja N, Grignani G, Quagliuolo V, Stoeckle E, De Paoli A, Pillarisetty VG, Nessim C, Swallow CJ, Bagaria S, Canter R, Mullen J, Gelderblom HJ, Pennacchioli E, van Coevorden F, Cardona K, Fiore M, Fairweather M, **Gronchi A**. Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. *Clin Cancer Res* in press
334. Tseng WW, Pasquali S, Hu JS, Menendez LR, **Gronchi A**. Staging Systems and Nomograms in Soft Tissue Sarcoma: Outcome Prediction by Categorization or Personalization? *Chin Clin Oncol* in press
335. Van Houdt W, Raut CP, Bonvalot S, Swallow CJ, Haas RL and **Gronchi A**. New research strategies in retroperitoneal sarcoma: the case of TARPSWG, STRASS and RESAR – making progress through collaboration. *Curr Opin Oncol* in press
336. **Gronchi A**, Hindi N, Cruz J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón I, Sangalli C, Pérez Aguiar JL, Romero J, Morosi C, Sunyach MP, Sanfilippo R, Romagosa C, Ranchere-Vince D, Dei Tos AP, Casali PG, Martin-Broto J. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): results of a phase I study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. *EClinicalMedicine* in press
- 337.

List of **Medline-non indexed scientific publications, in English**

- **Gronchi A**, Casali PG, Olmi P. Sacro-coccygeal chordoma: diagnosis and treatment review. *Sem Col Rectal Surg*, 2004; 15(1): 26-32.
- **Gronchi A**, Casali PG The impact of systemic treatment on patient survival of soft tissue sarcoma. *Eur Oncol* in press
- Thomas DM, **Gronchi A**, O'Sullivan B. A multidisciplinary approach to retroperitoneal sarcoma. *Am Soc Clin Oncol Ed Book* 1701-1708, 2009
- Pennacchioli E, Colombo C, Berselli M and **Gronchi A**. Update on management of GIST and postsurgical use of imatinib. *Open Access Surgery* 2010; 3: 63-71.
- Radaelli S, Desai A, Colombo C, Fiore M and **Gronchi A**. Perioperative therapies for localized retroperitoneal soft tissue sarcoma. *Oncology and Hematology Review* 2012; 8(1): 65-70

Annex 3

List of Book chapters, in English

- **Gronchi A** and Fiore M. Chordoma. In Khatri VP ed: Clinical Scenarios in Surgical Oncology. Philadelphia: Lippincott Williams & Wilkins; 2006: 299-302.
- Santinami M, **Gronchi A**, Maurichi M, Zoras O, Patuzzo R, Pennacchioli E. Limb's perfusion: rationale, techniques and results. In Zoras O ed: Regional Oncotherapies. Athens: Paschalidis Medical Publications Ltd; 2006:193-226.
- **Gronchi A**, Colombo C and Fiore M. Surgery of Primary Tumor. In Blay JY ed: 100 Key Questions on Soft Tissue Sarcoma. Mallorca: Permanyer Publications; 2010: 55-67.
- **Gronchi A**, Fiore M, Palaia R. Surgical Treatment. In de Lutio di Castelguidone E and Messina A eds: GISTs - Gastrointestinal Stromal Tumors. Milan: Springer Verlag Italia; 2011: 107-112.
- Fletcher CDM, Singer S, **Gronchi A**. Tumor of Soft Tissue: Introduction. In Fletcher CDM, Bridge JA, Hogendoorn PCW and Mertens F eds: WHO Classification of Tumours of Soft Tissue and Bone. Lyon; IARC; 2013: 14-16
- **Gronchi A**. Surgical Management of Soft Tissue Sarcomas. In Blay JY ed. Atlas of data and images on STS. Madrid; Grupo Editorial Entheos. 2013: 177-231
- Raut CP and **Gronchi A**. The management of Soft Tissue Sarcoma. In Cameron JL and Cameron AM eds: Current Surgical Therapy. Philadelphia: Elsevier Saunders; 2014: 706-717
- Comier JN, **Gronchi A** and Pollock RE. Soft Tissue Sarcoma. In Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, Pollock RE eds: Schwartz's Principles of Surgery. New York: McGraw-Hill Professional; 2014: 1465-1493
- Casali PG, Dei Tos AP and **Gronchi A**. Gastrointestinal Stromal Tumor. In DeVita, Hellman, and Rosenberg eds: Cancer. Principles & Practice of Oncology. Philadelphia Wolters Kluwer Health; 2015: 745-756
- **Gronchi A**, Dei Tos AP, Casali PG. Sarcomas of Soft Tissue and Bone. In Kerr DJ, Haller DG, van de Velde CJH, Baumann M eds: Oxford Textbook of Oncology. Oxford: Oxford University Press; 2016: 844-866
- Fontana A, Callegaro D and **Gronchi A**. Standard of care in early phases. In Blay JY ed: 100 Key Questions on Soft Tissue Sarcoma. Mallorca: Permanyer Publications; 2016: 17-28
- Sandrucci S, Stacchiotti S and **Gronchi A**. Retroperitoneal Sarcoma. In Poston G, Wyld L, Audisio RA eds: Surgical Oncology. Theory and Multidisciplinary Practice. Boca Raton: CRC Press Taylor & Francis Group; 2017: 617-629
- Fiore M, Radaelli S and **Gronchi A**. Retroperitoneal Sarcoma involving the Inferior Vena Cava. In Azoulay D, Lim C, Salloum eds: Surgery of the Inferior Vena Cava: multidisciplinary approach. Cham: Springer International Publishing Switzerland; 2017: 61-74
- Radaelli S, Colombo C, Fiore M and **Gronchi A**. Soft Tissue Tumors of the Groin and Inguinal region. In Delman KA and Master VA eds: Malignancies of the Groin. Springer International Publishing Switzerland; 2017: 123-157
- Quagliuolo V and **Gronchi A**. Eds. Current treatment of Retroperitoneal Sarcoma: a joint effort with the Italian Society of Surgical Oncology. Springer-Verlag Italia; 2018
- Casali PG, Dei Tos AP and **Gronchi A**. Gastrointestinal Stromal Tumor. In DeVita, Hellman, and Rosenberg eds: Cancer. Principles & Practice of Oncology. Philadelphia Wolters Kluwer Health; 2019: 895-906
-

Annex 4

List of Books, in Italian (or other national languages)

- Azzarelli A, **Gronchi A**, De Pas T, Marsiglia HR. Strategia terapeutica integrata in Sarcomi delle parti molli. In Veronesi U ed. Oncologia Chirurgica. Milano: Masson; 1999: 869-875.
- Casali PG, **Gronchi A**, Olmi P, Rosai J. Basi scientifiche per la definizione di linee guida in ambito clinico per i sarcomi dei tessuti molli dell'adulto. In Silvestrini R ed. Progetto Strategico Oncologia. Milano: CNR-MIUR; 2002.
- Casali PG, **Gronchi A**, Olmi P e Azzarelli A. Sarcomi delle parti molli dell'adulto. In Bonadonna G, Robustelli della Cuna G, Valagussa P, eds Medicina Oncologica. Milano: Masson; 2003: 1261-1274.
- Mussi C and **Gronchi A**. Tumori primitivi della parete addominale. In Croce, Olmi eds Chirurgia della parete addominale. Milano: Masson; 2006: 299-305.
- Mussi C and **Gronchi A**. Tumore desmoide. In Croce, Olmi eds Chirurgia della parete addominale. Milano: Masson; 2006: 307-310.
- **Gronchi A**, Colombo C and Fiore M. Il ruolo della chirurgia. In A. Comandone e S. Barni eds. I sarcomi dei Tessuti Molli. Roma: Il Pensiero Scientifico Editore; 2011: 103-123.
- Casali PG, Comandone A, Ferrari S, **Gronchi A**, Dei Tos AP. Sarcomi. In Cascinu S, Labianca R eds. La medicina Oncologica. Diagnosi, terapia e gestione clinica. Roma: Edra; 2013:
- Hindi Muniz N and **Gronchi A**. Tratamiento quirurgico (principios generales en extremidades y pared del tronco). In Martin-Broto J, Cruz J, Valverde C Y Cubedo R eds. Tratado de Sarcomas de Partes Blandas. Madrid: Nature Publishing Group Iberoamerica; 2015: 83-96

Annex 5

List of Clinical Trials Performed

- Localized High-Risk Soft Tissue Sarcomas of the Extremities and Superficial Trunk in Adults: an Integrated Approach Comprising 3 or 5 Cycles of Adjuvant Chemotherapy. A prospective controlled randomized trial from Italians Sarcoma Group and Spanish Sarcoma Group. **Principal Investigator.** Study accrual closed in 2007 (328 patients recruited). Reported at ASCO as oral presentation in 2010. Published on J Clin Oncol in 2012 and Ann Oncol in 2016
- A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (YONDELIS®) in Patients with Localized Myxoid / Round Cell Liposarcoma. **Principal Investigator.** Study accrual closed in 2009 (30 patients recruited); reported at ESMO as oral presentation in 2009 and at ASCO as poster discussion in 2009. Published in Ann Oncol in 2012.
- Preoperative Chemo-Radiation Therapy in Retroperitoneal Soft Tissue Sarcomas (\pm Radiation Boost). A multicentric phase II study from Italian Sarcoma Group. **Principal Investigator.** Study accrual closed in 2010 (86 patients recruited). Preliminary results reported at ASCO as poster discussion and at CTOS as oral presentation in 2011. Final results reported at ASCO in 2013 as poster discussion. Published in Eur J Cancer in 2014 and Ann Surg Oncol in 2017
- A Phase III Randomized Study Evaluating Surgery of Residual Disease in Patients with Metastatic Gastro-Intestinal Stromal Tumor Responding to Imatinib Mesylate. A EORTC study (62063). **Principal Investigator.** Closed in advance for poor accrual in 2011 (12 patients recruited)
- Localized High-Risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults: an Integrating Approach Comprising Standard vs Histotype-Tailored Neoadjuvant Chemotherapy. **Principal Investigator.** Accrual started in 2011. Interim Analysis published in Lancet Oncol in 2017
- A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma. A EORTC study (62092-22092). **Coinvestigator.** Accrual started in 2012
- Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoids tumor patients: an observational study. **Principal Investigator.** Accrual started in 2013
- Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus **RA**diotherapy in **Soft Tissue Sarcoma** patients (TRASTS). **Principal Investigator.** Accrual started in 2015
- NBTXR3-301 - A multicenter randomized, open-label phase II/III study, to compare the efficacy of NBTXR3, implanted as intratumor injection and activated by radiotherapy, versus radiotherapy alone in patients with locally advanced soft tissue sarcoma of the extremity and trunk wall. **Coinvestigator.** Accrual started in 2016
- SACral Chordoma: a Randomized & Observational study on surgery versus definitive radiation therapy in primary localized disease (SACRO). **Principal Investigator.** Accrual started in 2017
- REtroperitoneal SARcoma Registry (RESAR): prospective collection of primary retroperitoneal sarcoma patient's data, radiological and pathological material for the TransAtlantic Retroperitoneal Sarcoma Working Group. **Principal Investigator.** Accrual started in 2017
-